U.S. patent application number 16/596495 was filed with the patent office on 2020-04-09 for compositions and methods for obtaining stem cell derived lung tissue, and related uses therof.
The applicant listed for this patent is The Regents of the University of Michigan. Invention is credited to Briana Dye, Jason Spence.
Application Number | 20200109371 16/596495 |
Document ID | / |
Family ID | 57147421 |
Filed Date | 2020-04-09 |
![](/patent/app/20200109371/US20200109371A1-20200409-D00001.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00002.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00003.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00004.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00005.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00006.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00007.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00008.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00009.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00010.png)
![](/patent/app/20200109371/US20200109371A1-20200409-D00011.png)
View All Diagrams
United States Patent
Application |
20200109371 |
Kind Code |
A1 |
Spence; Jason ; et
al. |
April 9, 2020 |
COMPOSITIONS AND METHODS FOR OBTAINING STEM CELL DERIVED LUNG
TISSUE, AND RELATED USES THEROF
Abstract
The invention disclosed herein generally relates to methods and
systems for converting stem cells into specific tissue(s) or
organ(s) through directed differentiation. In particular, the
invention disclosed herein relates to methods and systems for
promoting definitive endoderm formation from pluripotent stem
cells. The invention disclosed herein further relates to methods
and systems for promoting ventral-anterior foregut spheroid tissue
formation, 3-dimensional lung tissue formation, and lung organoid
tissue formation produced in vitro from the described methods
Inventors: |
Spence; Jason; (Ann Arbor,
MI) ; Dye; Briana; (Ann Arbor, MI) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The Regents of the University of Michigan |
Ann Arbor |
MI |
US |
|
|
Family ID: |
57147421 |
Appl. No.: |
16/596495 |
Filed: |
October 8, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15134498 |
Apr 21, 2016 |
10557124 |
|
|
16596495 |
|
|
|
|
62151238 |
Apr 22, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N 2501/155 20130101;
C12N 2501/16 20130101; C12N 2501/119 20130101; C12N 2506/02
20130101; C12N 2501/41 20130101; C12N 5/0688 20130101; C12N
2501/415 20130101; C12N 2501/15 20130101 |
International
Class: |
C12N 5/071 20060101
C12N005/071 |
Goverment Interests
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under
HL115372 awarded by the National Institutes of Health. The
Government has certain rights in the invention.
Claims
1. A method, comprising: culturing definitive endoderm cells in
vitro, wherein the culturing results in differentiation of the
definitive endoderm cells into tissue comprising ventral-anterior
foregut spheroid tissue, wherein the culturing comprises activating
and/or inhibiting one or more signaling pathways within the
definitive endoderm cells, wherein the one or more signaling
pathways are selected from the group consisting of the Wnt
signaling pathway, the FGF signaling pathway, the BMP signaling
pathway, and the TGF.beta. signaling pathway; and obtaining
ventral-anterior foregut spheroid tissue from the cultured
definitive endoderm cells.
2. The method of claim 1, wherein the activating and/or inhibiting
one or more signaling pathways within the definitive endoderm cells
comprises activating the Wnt and FGF signaling pathways and
inhibiting the BMP and TGF.beta. signaling pathways, wherein
activating the Wnt signaling pathway within the definitive endoderm
cells comprises culturing the definitive endoderm cells with a
small molecule or agonist that activates the Wnt signaling pathway,
wherein activating the FGF signaling pathway within the definitive
endoderm cells comprises culturing the definitive endoderm cells
with a small molecule or agonist that activates the FGF signaling
pathway, wherein inhibiting the BMP signaling pathway within the
definitive endoderm cells comprises culturing the definitive
endoderm cells with a small molecule or antagonist that inhibits
the BMP signaling pathway, wherein inhibiting the TGF.beta.
signaling pathway within the definitive endoderm cells comprises
culturing the definitive endoderm cells with a small molecule or
antagonist that inhibits the TGF.beta. signaling pathway.
3. The method of claim 2, wherein the small molecule or agonist
that activates the Wnt signaling pathway is CHIR99021, wherein the
small molecule or agonist that activates the FGF signaling pathway
is selected from FGF1, FGF2, FGF3, FGF4, FGF10, FGF11, FGF12,
FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21,
FGF22, and FGF23, wherein the small molecule or antagonist that
inhibits the BMP signaling pathway is Noggin, wherein the small
molecule or antagonist that inhibits the TGF.beta. signaling
pathway is SB431542.
4. The method of claim 1, wherein activating the Wnt signaling
pathway occurs through culturing the definitive endoderm cells with
one or more molecules configured to activate a Wnt protein, wherein
the Wnt protein is selected from the group consisting of Wnt1,
Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b,
Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, and Wnt16.
5. The method of claim 1, comprising at least one of the following:
wherein the activating and/or inhibiting one or more signaling
pathways within the definitive endoderm cells occurs over a
specified temporal period, wherein the activating and/or inhibiting
one or more signaling pathways within the definitive endoderm cells
occurs comprises activating and/or inhibiting two or more signaling
pathways, wherein the activating and/or inhibiting two or more
signaling pathways occurs simultaneously, wherein the activating
and/or inhibiting two or more signaling pathways does not occur
simultaneously.
6. The method of claim 1, wherein the definitive endoderm cells are
derived from pluripotent stem cells, wherein the pluripotent stem
cells are embryonic stem cells and/or induced pluripotent stem
cells.
7. The method of claim 6, wherein the definitive endoderm cells are
derived by contacting the pluripotent stem cell with Activin A.
8. The method of claim 1, further comprising: culturing the
obtained ventral-anterior foregut spheroid tissue in vitro, wherein
the culturing results in differentiation of the obtained
ventral-anterior foregut spheroid tissue into tissue comprising
3-dimensional lung tissue, wherein the culturing comprising
activating the Hedgehog signaling pathway; and obtaining
3-dimensional lung tissue from the cultured tissue comprising
ventral-anterior foregut spheroid tissue.
9. The method of claim 8, wherein culturing the obtained
ventral-anterior foregut spheroid tissue through activating the
Hedgehog signaling pathway comprises culturing the ventral-anterior
foregut spheroid tissue with a small molecule or agonist that
activates the Hedgehog signaling pathway.
10. The method of claim 9, wherein the small molecule or agonist
that activates the Hedgehog signaling pathway is smoothened agonist
(SAG).
11. The method of claim 8, further comprising: culturing the
obtained 3-dimensional lung tissue in vitro, wherein the culturing
results in differentiation of the obtained tissue comprising
3-dimensional lung tissue into tissue lung organoid tissue, wherein
the culturing comprising activating the FGF signaling pathway; and
obtaining lung organoid tissue from the cultured 3-dimensional lung
tissue.
12. The method of claim 11, wherein culturing the obtained
3-dimensional lung tissue through activating the FGF signaling
pathway comprises culturing the obtained 3-dimensional lung tissue
with a small molecule or agonist that activates the FGF signaling
pathway.
13. The method of claim 12, wherein the small molecule or agonist
that activates the FGF signaling pathway is selected from FGF1,
FGF2, FGF3, FGF4, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16,
FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, and FGF23.
14. The method of claim 12, wherein the small molecule or agonist
that activates the FGF signaling pathway is FGF10.
15. The method of claim 11, wherein the obtained lung organoid
tissue comprises one or more of upper airway-like epithelium with
basal cells, immature ciliated cells surrounded by smooth muscle
and myofibroblasts, and alveolar-like cells.
16. The method of claim 1, wherein the culturing and obtaining
steps are conducted in vitro.
17. A composition comprising one or more of ventral-anterior
foregut spheroid tissue, 3-dimensional lung tissue, and lung
organoid tissue.
18. A kit comprising one or more of ventral-anterior foregut
spheroid tissue, 3-dimensional lung tissue, and lung organoid
tissue.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present invention of is a Continuation of U.S. patent
application Ser. No. 15/134,498 filed Apr. 21, 2016 which claims
priority to U.S. Provisional Patent Application 62/151,238, filed
Apr. 22, 2015, which is incorporated by reference in its
entirety.
SEQUENCE LISTING
[0003] The text of the computer readable sequence listing filed
herewith, titled "34369-303_SEQUENCE_LISTING_ST25", created Dec. 9,
2019, having a file size of 8,000 bytes, is hereby incorporated by
reference in its entirety.
FIELD OF THE INVENTION
[0004] The invention disclosed herein generally relates to methods
and systems for converting stem cells into specific tissue(s) or
organ(s) through directed differentiation. In particular, the
invention disclosed herein relates to methods and systems for
promoting definitive endoderm formation from pluripotent stem
cells. The invention disclosed herein further relates to methods
and systems for promoting ventral-anterior foregut spheroid tissue
formation, 3-dimensional lung tissue formation, and lung organoid
tissue formation produced in vitro from the described methods
INTRODUCTION
[0005] Pluripotent stem cells (PSCs) are the descendants of
totipotent cells and can differentiate into nearly all cells, i.e.,
cells derived from any of the three germ layers, including endoderm
(interior stomach lining, gastrointestinal tract, the lungs),
mesoderm (muscle, bone, blood, urogenital), and ectoderm (epidermal
tissues and nervous system).
[0006] Embryonic and induced pluripotent stem cells have had an
unprecedented impact on the ability to study human diseases and to
generate replacement tissues that are therapeutically effective in
animal models.
[0007] In developmental biology, cellular differentiation is the
process by which a less specialized cell becomes a more specialized
cell type. Most successful efforts to direct the differentiation of
human PSCs into therapeutic cell types have been based on studies
of embryonic organ development. Examples include the generation of
liver hepatocytes and pancreatic endocrine cells, which have shown
functional potential in animal models of liver disease and
diabetes. Similarly, differentiation of PSCs into lung tissue may
provide therapeutic benefit for diseases such as end stage lung
disease.
[0008] Pluripotent stem cells have the potential to differentiate
into any of the three germ layers: endoderm (interior stomach
lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone,
blood, urogenital), and ectoderm (epidermal tissues and nervous
system). As such, pluripotent stem cells can give rise to any fetal
or adult cell type. However, the fate of the particular pluripotent
stem cells is controlled by numerous cellular signaling pathway and
numerous factors. Further, the pluripotent stem cells alone cannot
develop into a fetal or adult animal because they lack the
potential to contribute to extraembryonic tissue, such as the
placenta.
[0009] What is needed in the art are methods and systems for
accurately controlling the destination of the pluripotent stem
cells in order to create the specific type of tissue or organism of
desire.
SUMMARY OF THE INVENTION
[0010] Breakthroughs in 3-dimensional (3D) organoid cultures for
many organ systems have led to new physiologically complex in vitro
models to study human development and disease. Experiments
conducted during the course of developing embodiments for the
present invention demonstrate step-wise differentiation of human
pluripotent stem cells (hPSCs) (embryonic and induced) into lung
organoids. Indeed, it was shown that by manipulating developmental
signaling pathways hPSCs generate ventral-anterior foregut
spheroids, which are then expanded into human lung organoids
(HLOs). Such HLOs were shown to consist of epithelial and
mesenchymal compartments of the lung, organized with structural
features similar to the native lung. Such HLOs were shown to
possess upper airway-like epithelium with basal cells and immature
ciliated cells surrounded by smooth muscle and myofibroblasts, as
well as an alveolar-like domain with appropriate cell types.
Moreover, using RNA-sequencing, it was shown that HLOs are
remarkably similar to human fetal lung based on global
transcriptional profiles, thereby indicating that HLOs are an
excellent model to study human lung development, maturation and
disease.
[0011] Accordingly, the invention disclosed herein generally
relates to methods and systems for converting stem cells into
specific tissue(s) or organ(s) through directed differentiation. In
particular, the invention disclosed herein relates to methods and
systems for promoting definitive endoderm formation from
pluripotent stem cells. The invention disclosed herein further
relates to methods and systems for promoting ventral-anterior
foregut spheroid tissue formation, 3-dimensional lung tissue
formation, and lung organoid tissue formation produced in vitro
from the described methods
[0012] In certain embodiments, the present invention provides
methods of inducing formation of lung organoid tissue, comprising
culturing definitive endoderm cells in vitro, wherein the culturing
results in differentiation of the definitive endoderm cells into
tissue comprising ventral-anterior foregut spheroid tissue, wherein
the culturing comprises activating and/or inhibiting one or more
signaling pathways within the definitive endoderm cells, wherein
the one or more signaling pathways are selected from the group
consisting of the Wnt signaling pathway, the FGF signaling pathway,
the BMP signaling pathway, and the TGF.beta. signaling pathway;
obtaining ventral-anterior foregut spheroid tissue from the
cultured definitive endoderm cells; culturing the obtained
ventral-anterior foregut spheroid tissue in vitro, wherein the
culturing results in differentiation of the obtained
ventral-anterior foregut spheroid tissue into tissue comprising
3-dimensional lung tissue, wherein the culturing comprising
activating the Hedgehog signaling pathway; obtaining 3-dimensional
lung tissue from the cultured tissue comprising ventral-anterior
foregut spheroid tissue; culturing the obtained 3-dimensional lung
tissue in vitro, wherein the culturing results in differentiation
of the obtained tissue comprising 3-dimensional lung tissue into
tissue lung organoid tissue, wherein the culturing comprising
activating the FGF signaling pathway; and obtaining lung organoid
tissue from the cultured 3-dimensional lung tissue.
[0013] In certain embodiments, the present invention provides
methods of inducing formation of 3-dimensional lung tissue,
comprising culturing definitive endoderm cells in vitro, wherein
the culturing results in differentiation of the definitive endoderm
cells into tissue comprising ventral-anterior foregut spheroid
tissue, wherein the culturing comprises activating and/or
inhibiting one or more signaling pathways within the definitive
endoderm cells, wherein the one or more signaling pathways are
selected from the group consisting of the Wnt signaling pathway,
the FGF signaling pathway, the BMP signaling pathway, and the
TGF.beta. signaling pathway; obtaining ventral-anterior foregut
spheroid tissue from the cultured definitive endoderm cells;
culturing the obtained ventral-anterior foregut spheroid tissue in
vitro, wherein the culturing results in differentiation of the
obtained ventral-anterior foregut spheroid tissue into tissue
comprising 3-dimensional lung tissue, wherein the culturing
comprising activating the Hedgehog signaling pathway; and obtaining
3-dimensional lung tissue from the cultured tissue comprising
ventral-anterior foregut spheroid tissue.
[0014] In certain embodiments, the present invention provides
methods of inducing formation of ventral-anterior foregut spheroid
tissue, comprising culturing definitive endoderm cells in vitro,
wherein the culturing results in differentiation of the definitive
endoderm cells into tissue comprising ventral-anterior foregut
spheroid tissue, wherein the culturing comprises activating and/or
inhibiting one or more signaling pathways within the definitive
endoderm cells, wherein the one or more signaling pathways are
selected from the group consisting of the Wnt signaling pathway,
the FGF signaling pathway, the BMP signaling pathway, and the
TGF.beta. signaling pathway; obtaining ventral-anterior foregut
spheroid tissue from the cultured definitive endoderm cells.
[0015] Such methods are not limited to activating a particular
signaling pathway within the definitive endoderm cells. In some
embodiments, the activated signaling pathway is one or more of the
Wnt and FGF signaling pathways.
[0016] Such methods are not limited to inhibiting a particular
signaling pathway within the definitive endoderm cells. In some
embodiments, the inhibited signaling pathway is one or both of the
BMP and TGF-.beta. signaling pathways.
[0017] In some embodiments, such methods comprise activating the
Wnt and FGF signaling pathways and inhibiting the BMP and TGF.beta.
signaling pathways within the definitive endoderm cells.
[0018] Such methods are not limited to a particular manner of
activating the Wnt signaling pathway within the definitive endoderm
cells. In some embodiments, activating the Wnt signaling pathway
within the definitive endoderm cells comprises culturing the
definitive endoderm cells with a small molecule or agonist that
activates the Wnt signaling pathway. In some embodiments, the small
molecule or agonist that activates the Wnt signaling pathway is
CHIR99021. In some embodiments, activating the Wnt signaling
pathway occurs through culturing the definitive endoderm cells with
one or more molecules configured to activate a Wnt protein, wherein
the Wnt protein is selected from the group consisting of Wnt1,
Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b,
Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, and Wnt16. In
some embodiments, activating the Wnt signaling pathway comprises
culturing the definitive endoderm cells with a small molecule or
other agonist that stimulates Wnt signaling. In some embodiments,
the Wnt agonist is CHIR99021.
[0019] Such methods are not limited to a particular manner of
activating the FGF signaling pathway within the definitive endoderm
cells. In some embodiments, activating the FGF signaling pathway
occurs through culturing the definitive endoderm cells with one or
more molecules configured to activate a FGF protein, wherein the
FGF protein is selected from the group consisting of FGF1, FGF2,
FGF3, FGF4, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17,
FGF18, FGF19, FGF20, FGF21, FGF22, and FGF23. In some embodiments,
activating the FGF signaling pathway within the definitive endoderm
cells comprises culturing the definitive endoderm cells with a
small molecule or agonist that activates the FGF signaling pathway.
In some embodiments, the small molecule or agonist that activates
the FGF signaling pathway is FGF4.
[0020] Such methods are not limited to a particular manner of
inhibiting the BMP signaling pathway within the definitive endoderm
cells. In some embodiments, inhibiting the BMP signaling pathway
within the definitive endoderm cells comprises culturing the
definitive endoderm cells with a small molecule or antagonist that
inhibits the BMP signaling pathway. In some embodiments, the small
molecule or antagonist that inhibits the BMP signaling pathway is
Noggin.
[0021] Such methods are not limited to a particular manner of
inhibiting the TGF.beta. signaling pathway within the definitive
endoderm cells. In some embodiments, inhibiting the TGF.beta.
signaling pathway within the definitive endoderm cells comprises
culturing the definitive endoderm cells with a small molecule or
antagonist that inhibits the TGF.beta. signaling pathway. In some
embodiments, the small molecule or antagonist that inhibits the
TGF.beta. signaling pathway is SB431542.
[0022] In some embodiments, activating and/or inhibiting one or
more signaling pathways within the definitive endoderm cells
comprises culturing the definitive endoderm cells with a Wnt
signaling pathway agonist, a FGF signaling pathway agonist, a BMP
signaling pathway inhibitor, and a TGF.beta. signaling pathway
inhibitor.
[0023] In some embodiments, activating and/or inhibiting one or
more signaling pathways within the definitive endoderm cells
comprises culturing the definitive endoderm cells with CHIR99021,
FGF4, Noggin, and SB431542.
[0024] In some embodiments, activating and/or inhibiting one or
more signaling pathways within the definitive endoderm cells occurs
over a specified temporal period.
[0025] In some embodiments, activating and/or inhibiting one or
more signaling pathways within the definitive endoderm cells occurs
comprises activating and/or inhibiting two or more signaling
pathways. In some embodiments, the activating and/or inhibiting two
or more signaling pathways occurs simultaneously. In some
embodiments, the activating and/or inhibiting two or more signaling
pathways does not occur simultaneously.
[0026] In some embodiments, the definitive endoderm cells are
derived from pluripotent stem cells. In some embodiments, the
pluripotent stem cells are embryonic stem cells and/or induced
pluripotent stem cells. In some embodiments, the definitive
endoderm cells are derived by contacting the pluripotent stem cell
with Activin A. In some embodiments, the pluripotent stem cells are
human pluripotent stem cells.
[0027] Such methods are not limited to a particular manner of
activating the Hedgehog signaling pathway within the obtained
ventral-anterior foregut spheroid tissue. In some embodiments,
culturing the obtained ventral-anterior foregut spheroid tissue
occurs through activating the Hedgehog signaling pathway occurs
through culturing the obtained ventral-anterior foregut spheroid
tissue with a small molecule or agonist that activates the Hedgehog
signaling pathway. In some embodiments, the small molecule or
agonist that activates the Hedgehog signaling pathway is smoothened
agonist (SAG).
[0028] Such methods are not limited to a particular manner of
activating the FGF signaling pathway within the obtained
3-dimensional lung tissue. In some embodiments, culturing the
obtained 3-dimensional lung tissue through activating the FGF
signaling pathway occurs through culturing the obtained
3-dimensional lung tissue with a small molecule or agonist that
activates the FGF signaling pathway. In some embodiments, the small
molecule or agonist that activates the FGF signaling pathway is
selected from FGF1, FGF2, FGF3, FGF4, FGF10, FGF11, FGF12, FGF13,
FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, and
FGF23. In some embodiments, the small molecule or agonist that
activates the FGF signaling pathway is FGF10.
[0029] In some embodiments, the culturing and obtaining steps are
conducted in vitro.
[0030] In some embodiments, the obtained lung organoid tissue
comprises one or more of upper airway-like epithelium with basal
cells, immature ciliated cells surrounded by smooth muscle and
myofibroblasts, and alveolar-like cells.
[0031] In certain embodiments, the present invention provides
compositions comprising or consisting of ventral-anterior foregut
spheroid tissue produced in vitro from the described methods.
[0032] In certain embodiments, the present invention provides
compositions comprising or consisting of 3-dimensional lung tissue
produced in vitro from the described methods.
[0033] In certain embodiments, the present invention provides
compositions comprising or consisting of lung organoid tissue
produced in vitro from the described methods.
[0034] In certain embodiments, the present invention provides
compositions comprising or consisting of ventral-anterior foregut
spheroid tissue, and/or 3-dimensional lung tissue, and/or lung
organoid tissue produced in vitro from the described methods.
[0035] In certain embodiments, the present invention provides kits
comprising ventral-anterior foregut spheroid tissue produced in
vitro from the described methods.
[0036] In certain embodiments, the present invention provides kits
comprising 3-dimensional lung tissue produced in vitro from the
described methods.
[0037] In certain embodiments, the present invention provides kits
comprising lung organoid tissue produced in vitro from the
described methods.
[0038] In certain embodiments, the present invention provides kits
comprising or consisting of ventral-anterior foregut spheroid
tissue, and/or 3-dimensional lung tissue, and/or lung organoid
tissue produced in vitro from the described methods.
BRIEF DESCRIPTION OF DRAWINGS
[0039] FIG. 1A-F: Generation of three-dimensional ventral anterior
foregut spheroids from endoderm monolayers. (A) hESCs were
differentiated into foregut endoderm by treating cells with 4 days
of Activin A (ACTA) followed by 4 days of NOG+SB. (B) Foregut
endoderm (NOG+SB) had high expression of the foregut marker SOX2
while the hindgut marker CDX2 was significantly reduced compared to
untreated endoderm controls (End). NOG+SB monolayer had high
expression of ventral anterior foregut genes NKX2.1 and PAX8 while
the posterior foregut marker PDX1 was reduced. The foregut marker
HHEX is expressed in the developing liver, biliary system, and
thyroid and remained unchanged. (C) The majority of cells in NOG+SB
treated cultures were SOX2 positive (gray-scaled green) compared to
the control, in which only scattered clusters of cells were SOX2
positive. Scale bar represents 200 .mu.m. (D) hESCs were
differentiated into foregut spheroids by treating cells with 4 days
of ACTA and then additional 4 to 6 days of NOG+SB+FGF4+Ch.
Representative images of a spheroid in a matrigel droplet shown as
whole mount image. Scale bar represents 100 .mu.m. (E) Foregut
spheroids (NOG+SB+FGF4+Ch) had high expression of the foregut
marker SOX2 while the hindgut marker CDX2 was significantly reduced
compared to untreated endoderm control (End) (top panel). Spheroids
had high expression of anterior foregut genes NKX2.1 and PAX8 while
the posterior foregut marker PDX1 was reduced and HHEX was
unchanged (bottom panel). *p<0.05, error bars represent SEM. (F)
The majority of cells in foregut spheroids are FOXA2+ (gray-scaled
green, left panel) and SOX2+ (white, right panel) and ECAD+
(gray-scaled red, right panel). Scale bar represent 50 .mu.m.
[0040] FIG. 2A-C: Monolayer cultures express lung specific markers.
Immunohistochemistry for markers expressed in endoderm, ventral
foregut or lung epithelium were assessed (SOX2, FOXA2, NKX2.1,
SOX9) in endoderm controls, foregut controls or foregut cultures
treated with SAG or SAG+SU. (A) All conditions express endoderm
marker FOXA2 (gray-scaled red), but the foregut (NOG+SB) control,
SAG and SAG+SU treated cultures have co-expression of FOXA2
(gray-scaled red) and SOX2 (gray-scaled green) in the majority of
cells. (B) All conditions expressed endoderm marker FOXA2
(gray-scaled red), but only foregut endoderm treated with SAG and
SAG+SU have robust NKX2.1+ cells (gray-scaled green) that also
express FOXA2 (gray-scaled red). (A-B) Scale bars represent 200
.mu.m and apply to all images. (C) Only foregut endoderm treated
with SAG and SAG+SU have robust NKX2.1+ cells (gray-scaled green)
with the majority of cell co-expressing with lung epithelial marker
SOX9 (gray-scaled red). Scale bar represents 100 .mu.m.
[0041] FIG. 3A-B: Foregut spheroids co-express endoderm and lung
specific markers. (A) NOG/SB/FGF4/Ch spheroids have weak NKX2.1
(gray-scaled green) expression which co-expresses with endoderm
marker FOXA2 (gray-scaled red). (B) The majority of cells in the
spheroid express SOX2 (gray-scaled green) and co-stain with FOXA2
(gray-scaled red). Scale bars represent 50 .mu.M.
[0042] FIG. 4: Foregut spheroids consist of both epithelial and
mesenchymal cells. NOG/SB/FGF4/Ch spheroids have a minor population
of Vimentin (VIM, white) positive mesenchymal cells, while the
majority of cells are epithelial and express ECAD (gray-scaled
red). Scale bar represents 50 .mu.M.
[0043] FIG. 5: NOG+SB+FGF4+Ch spheroids do not express neural
markers. hESCs were differentiated into endoderm by treating with 4
days of ActivinA (ACTA) and spheroids were generated with an
additional 4 days of NOG+SB+FGF4+Ch. Neural cultures were not
treated with ACTA, but were treated with NOG+SB for 8 days.
Compared to foregut spheroids (NOG+SB+FGF4+Ch), NOG+SB neural
cultures had a significant increase in neural markers NESTIN, SOX1,
and PAX6 and significant decrease in FOXA2, which is highly
expressed in endoderm. *p<0.05, error bars represent SEM.
[0044] FIG. 6A-D: Induction of NKX2.1 in anterior foregut endoderm
by modulating FGF and HH signaling. (A) hESCs were differentiated
into endoderm (End) or anterior foregut with NOG+SB (For). Anterior
foregut was treated with low (50 ng/mL) and high (500 ng/mL)
concentrations of FGF2. FGF2 caused a dose dependent increase in
SHH and PAX8 expression with a modest increase in NKX2.1 expression
compared to untreated endoderm controls. Note that NKX2.1
expression is increased by NOG+SB exposure alone (no FGF2). (B)
Addition of the FGF inhibitor SU5402 (SU) to NOG+SB foregut
cultures (For) caused a significant reduction of SHH and PAX8
expression, but NKX2.1, GLI1, and PTCH1 were not significantly
different compared to the foregut controls, in which no growth
factors were added after SB+NOG. (C) Addition of the HH inhibitor
Sant-2 caused a significant reduction in NKX2.1 compared to foregut
control. Similarly when FGF2 (500 ng/mL) and Sant-2 were added
simultaneously, the modest NKX2.1 induction caused by FGF2 was
significantly reduced whereas PAX8 expression remained unchanged.
(D) Foregut endoderm treated with SAG or SAG+SU for 8 days had a
6.5 fold and 21 fold increase of NKX2.1 expression, respectively,
compared to untreated foregut controls. PAX8 expression was
unchanged in the SAG treated cultures whereas SAG+SU treated
cultures demonstrated a 41 fold decrease in PAX8 expression.
End=endoderm; For=foregut in all panels. *p<0.05, error bars
represent SEM.
[0045] FIG. 7A-B: Robust induction of NKX2.1 in foregut endoderm
with HH stimulation and FGF inhibition. (A) Immunohistochemistry of
NKX2.1 and PAX8 in endoderm controls, foregut controls or foregut
cultures treated with SAG or SAG+SU. Treatment of foregut cultures
with SAG or SAG+SU resulted in more NKX2.1+ cells compared to
endoderm and foregut controls. Scale bars represent 200 .mu.m and
apply to all images. (B) Quantification showed that 20%+/-4% of
cells in foregut controls were NKX2.1+, whereas 72%+/-3% cells were
positive in SAG+SU treated cultures (*p<0.05). All error bars
represent SEM.
[0046] FIG. 8: Overview of conditions tested to generate human lung
organoids. hPSCs are OCT4 and NANOG positive. After 4 days of 100
ng/mL Activin A, definitive endoderm (FOXA2 and SOX17 positive) was
generated and then treated with two different conditions. In the
top branch, NOG+SB+FGF4+Ch spheroids were generated, and different
conditions were tested to promote lung organoid differentiation. In
the bottom branch, NOG+SB+FGF4+Ch+SAG spheroids were generated, and
different conditions were tested to promote lung organoid
differentiation. Ultimately, it was determined that spheroids
generated with NOG+SB+FGF4+Ch+SAG and that were subsequently
embedded in Matrigel and expanded in FGF10 gave rise to "Human Lung
Organoids" (HLOs).
[0047] FIG. 9A-E: FGF-low culture conditions cause a loss of
organoid epithelium over time. (A) NOG+SB+F+Ch foregut spheroids
were generated and then cultured in SAG+SU for 10 days followed by
1% FBS+/-FGF10. Timeline images show organoids cultured in 1% FBS.
By day 20, 3D structures appeared "fuzzy", which indicates an
outgrowth of mesenchymal tissue. Scale bar represents 200 .mu.m.
(B) NOG+SB+F+Ch foregut spheroids treated with SAG+SU and
maintained in 1% FBS showed an increase in Vimentin (VIM,
gray-scaled green) immunofluorescence over time. Scale bar
represents 50 .mu.M. (C) NOG+SB+F+Ch foregut spheroids treated with
SAG+SU and maintained in 1% FBS (upper panel) or 1% FBS+FGF10
(lower panel) had a significant increase of VIM expression starting
at day 20 (D20) compared to hPSCs and showed very weak E-CADHERIN
(CDH1) expression compared to D20 HLOS (optimized conditions, as
described in FIG. 10). Lastly, both conditions appeared to lose
NKX2.1 expression over time. (D) NOG+SB+F+Ch+SAG spheroids
maintained in 1% FBS (basal media) also appear to lose epithelial
structures over time. Scale bar represents 200 .mu.m. (E) By day 20
(D20) the tissue had very few epithelial structures expressing ECAD
(white, left panel) and there was robust VIM expression
(gray-scaled green, right panel) at both time points. Scale bar
represents 50 .mu.m. HLO. *p<0.05. All error bars represent
SEM.
[0048] FIG. 10A-E: HH-induced ventral foregut spheroids give rise
to lung organoids. (A) hESCs were differentiated into foregut
spheroids by treating cells with 4 days of ACTA and then additional
4 to 6 days of NOG+SB+FGF4+Ch with the addition of the HH agonist
SAG. Representative whole mount images of spheroids in a matrigel
droplet are shown at low (left, scale bar 200 .mu.m) and high
magnification (right, scale bar 100 .mu.m). (B) The addition of SAG
to the NOG+SB+FGF4+Ch spheres caused a reduction in SOX2 and CDX2
transcripts (top panel) and a significant increase of NKX2.1
transcript (bottom panel) compared to NOG+SB+FGF4+Ch spheres
(without SAG). Other foregut lineages (PAX8, PDX1, HHEX) were not
significantly different when SAG was added. (C) The majority of the
cells in NOG+SB+FGF4+Ch+SAG spheres expressed FOXA2, SOX2 and
NKX2.1 protein. Scale bars represent 50 .mu.m. (D) Timeline showing
NOG+SB+FGF4+Ch+SAG induced foregut spheroids grown and maintained
in FGF10. Note that Day 1 is the day spheroids were plated in
Matrigel. Scale bar represents 100 .mu.m. (E) Organoids express
lung markers in a manner consistent with mouse lung development.
All expression is shown relative to undifferentiated pluripotent
stem cells (hPSC), and adult human lung is shown as a reference.
Lung progenitor markers NMYC and ID2 were very low in adult lung,
and were expressed at high levels in early organoid cultures, but
were reduced over time (D=Days in culture), whereas NKX2.1
expression remained relatively constant. In contrast, SFTPC is
known to be expressed at low levels in distal lung progenitors, but
increases and is highly expressed in AECII cells. Consistently,
SFTPC is highly expressed in adult human lungs and increases over
time in organoid cultures and the AECI marker HOPX is also highly
expressed in adult human lung and increases over time in organoids.
*p<0.05. All error bars represent SEM.
[0049] FIG. 11A-B: Foregut spheroids express lung and foregut
specific markers. (A) NOG/SB/FGF4/Ch/SAG spheroids coexpress NKX2.1
(gray-scaled green) and the endoderm marker FOXA2 (gray-scaled
red). (B) The majority of the cells in the spheroid co-expresses
SOX2 (gray-scaled green) and FOXA2 gray-scaled (gray-scaled red).
Scale bars represent 50 .mu.M.
[0050] FIG. 12: Ventral foregut spheroids do not express
appreciable levels of PAX8 protein. Although NOG+SB+FGF4+Ch+SAG
ventral foregut spheroids expressed PAX8 mRNA (FIG. 10B), PAX8
protein was not detected in spheroids using immunofluorescence,
whereas PAX8 protein in FGF2 8 day treated foregut monolayers (ACTA
followed by NOG/SB) was readily detectable. Left panel: scale bar
represents 50 .mu.m. Right panel: scale bar represents 200 .mu.m,
inset scale bar represents 100 .mu.m.
[0051] FIG. 13: Foregut spheroids consist of both epithelial and
mesenchymal cells. NOG/SB/FGF4/Ch/SAG spheroids have a minor
population of Vimentin (VIM, white) positive mesenchymal cells,
while the majority of cells are epithelial and express ECAD
(gray-scaled red). Scale bar represents 50 .mu.M.
[0052] FIG. 14: Lung organoids contain both proximal and distal
domains. NOG/SB/FGF4/Ch/SAG spheroids cultured for 15 days with
FGF10 express the distal lung epithelium marker SOX9 (gray-scaled
green) and proximal marker SOX2 (white) as separate domains in the
epithelium labeled by ECAD (gray-scaled red). Z-stack images are
shown every 40 .mu.m sections through the HLO. Scale bar represents
200 .mu.m.
[0053] FIG. 15A-E: (A) Genes expressed in the proximal airway were
examined in organoids across time. The proximal airway cell marker
SOX2 decreased over time in HLOs cultures compared to D10 HLOs.
Compared to undifferentiated hPSCs, organoids expressed high levels
of the basal cell marker P63 at all time points, while the club
cell marker SCGB1A1 and ciliated cell marker FOXJ1 had a
significant increase of expression in prolonged cultures (compared
to D10 HLOs). There was an increasing but non-significant trend in
goblet cell MUC5AC expression over time in culture. (B) D65 HLOs
had structures resembling the proximal airway, in which the
epithelium (.beta.-catenin, gray-scaled red) possesses P63+ basal
cells (gray-scaled green), and is surrounded by SMA+ (white, upper
and lower left panel) mesenchymal tissue. Adjacent to the P63
positive basal cell layer (gray-scaled green, lower, right panel)
were FOXJ1 positive cells (white). Scale bars represent 50 .mu.M
(top) and 10 .mu.M (bottom). (C) Proximal airway-like epithelium
(.beta.-catenin, gray-scaled green) co-stained for ACTTUB on the
apical side of the cell (gray-scaled red). Scale bars represent 50
.mu.M (top) and 10 .mu.M (bottom). (D). Proximal airway-like
epithelium (E-cadherin, gray-scaled red) also co-stained with Club
cell marker CC10 (white, right panel). Scale bars represent 50
.mu.M (top) and 10 .mu.M (bottom). (E) Acellular human lung matrix
was seeded with spheroids and cultured for 40 days (D40). Matrices
had abundant proximal airway-like structures that had
multi-ciliated cells on the apical surfaced labeled by ACTTUB
(gray-scaled red, top panel) in low (scale bar 50 .mu.M) and high
magnification (scale bar 10 .mu.M). Serial sections showed that
cells were also FOXJ1 positive (white, lower panel) with the
epithelium outlined in ECAD (gray-scaled green) in low (scale bar
50 .mu.M) and high magnification (scale bar 10 .mu.M). (B-D) `L` in
high magnification images indicates the lumen. *p<0.05. All
error bars represent SEM.
[0054] FIG. 16A-B: Lung organoids have P63+ epithelium throughout
the organoid. (A) Confocal Z-slices taken at every 40 .mu.m show
P63+ (gray-scaled green) and ECAD+ (white) structures through the
D65 HLO. (B) Z-slices taken at every 40 .mu.m show SMA (white)
surrounding the periphery the HLO with P63 (gray-scaled green)
staining within the HLO. Scale bars represent 200 .mu.m.
[0055] FIG. 17A-B: P63+ cells have an NKX2.1+ lung identity. (A)
Serial sections were stained with NKX2.1 and P63 respectively. The
adjacent sections expressed ECAD (white) and NKX2.1 (gray-scaled
green) in the first section and P63 (gray-scaled green) in the
second section. (B) P63+ cells (gray-scaled green) co-expressed the
proximal lung marker SOX2 (gray-scaled red) in the epithelium
labeled by ECAD (white). Scale bars represent 50 .mu.m.
[0056] FIG. 18A-C: Lung organoids possess multiple types of
mesenchymal cells. (A) D65 HLOs have PDGFR.alpha.+ (gray-scaled
green) VIM+ (white) double-positive myofibroblasts and
PDGFR.alpha.-/VIM+ fibroblasts. Scale bar represents 50 .mu.m. (B)
D65 HLOs also possesses PDGFR.alpha.+ (gray-scaled green) SMA+
(white) double-positive myofibroblasts and PDGFR.alpha.-/SMA+
smooth muscle and myofibrblasts. Scale bar represents 50 .mu.m. (C)
D65 HLO do not contain any cartilage whereas positive control iPSC
derived teratoma had clear SafraninO staining specific to
cartilage. Fast gray-scaled green marks the cytoplasm and
hematoxylin the nuclei of both tissues. Scale bar represents 100
.mu.m.
[0057] FIG. 19A-D: Lung organoids possess abundant distal bipotent
progenitor cells. (A) The expression of the distal progenitor
marker SOX9 remained unchanged over time and the AECI marker PDPN
had low expression in HLO cultures. (B) The majority of SFTPC+
cells (gray-scaled green, left panel) co-expressed SOX9
(gray-scaled red). Similarly, many cells expressing the AECI early
marker HOPX+ (gray-scaled green, right panel) co-expressed SOX9
(gray-scaled red). Few, scattered cells expressed the late AECII
marker SFTPB (white, second panel) or the AECI marker, PDPN (third
panel, white). Few PDPN+ cells also showed elongated, squamous
morphology seen in the adult lung. (C) Human lung AECII cells
labeled with SFTPC (gray-scaled green, left panel) did not
co-express SOX9. SFTPB+ cells (white, second panel) in the adult
human lung have similar morphology to SFTPB+ cells in HLOs. Human
lung AECI cells expressed PDPN (white, third panel), and show
characteristic AECI cell shape. Human AECI cells express HOPX
(gray-scaled green, right panel), but did not co-express SOX9.
(B-C) Scale bar in lower magnification images in B (upper panel)
represent 50 .mu.M and higher magnification in B,C (lower panel)
represent 10 .mu.M. (D) D50 HLOs contain lamellar bodies which are
organelles specific to AECII cells. Scale bars represent 500
nm.
[0058] FIG. 20: SFTPC+ cells express lung specific markers. D65
HLOs express lung epithelial markers NKX2.1 (gray-scaled green) and
SOX9 (gray-scaled red) and the adjacent section expresses SFTPC
(gray-scaled green) and SOX9 (gray-scaled red). Scale bar
represents 50 .mu.m.
[0059] FIG. 21A-G: Quantitative assessment of the composition of
lung organoids. (A) HLOs were assessed for proximal airway-like
structures (P63+) and distal airway-like structures (P63-/SFTPC+).
81% of HLOs have proximal airway-like epithelium while 100% have
distal airway-like epithelium (n=48 individual HLOs). (B) The
average cross-sectional area within an HLO that is comprised of
P63+ proximal airway-like and P63- distal airway-like epithelium
was calculated. Proximal structures comprised 14.5% (+/-0.6%) of
the entire area of the HLO (P63+), whereas 85.5% (+/-0.6%) of HLO
was distal-like epithelium and mesenchyme (P63-). (C-G) The percent
of specific cell markers present in an organoid was determined by
dividing by the total number of Dapi+ nuclei within the same
section (n=15 individual HLOs). Each point represents the data from
an individual HLO while the open bar represents the average percent
of cells. (C) On average, 57% of all cells in the HLOs were
NKX2.1+, (D) 39% of all cells were P63+, (E) 3% were FOXJ1+, (F) 5%
were SFTPC+, (G) 4% of all cells were HOPX+. (B-G) Error bars
represent SEM.
[0060] FIG. 22: A table showing publicly available RNAseq datasets
utilized for human fetal lung representing a range of gestational
stages, and for adult human lung (see, Example VII).
[0061] FIG. 23A-D: RNA sequencing analysis associates HLOs with
fetal lung tissue. 6 HLOs (n=3 D65 HLOs and n=3 D110 HLOs) were
compared to the undifferentiated H9 stem cells (SC) and definitive
endoderm (Def End) and publicly available datasets of adult and
fetal human lungs (see Supplemental Table 1). (A-B) Principle
component (PC) analysis, (C) hierarchical clustering, and (D)
Spearman's correlation all demonstrate that HLOs are most closely
related to the fetal lung.
[0062] FIG. 24: A table providing antibody information and
dilutions as described in Example VIII.
[0063] FIG. 25: A table providing a list of primer sequences
utilized in RNA extraction and qRT-PCR as described in Example
VIII.
DEFINITIONS
[0064] As used herein, the term "pluripotent stem cells (PSCs),"
also commonly known as PS cells, encompasses any cells that can
differentiate into nearly all cells, i.e., cells derived from any
of the three germ layers (germinal epithelium), including endoderm
(interior stomach lining, gastrointestinal tract, the lungs),
mesoderm (muscle, bone, blood, urogenital), and ectoderm (epidermal
tissues and nervous system). PSCs can be the descendants of
totipotent cells, derived from embryonic stem cells (including
embryonic germ cells) or obtained through induction of a
non-pluripotent cell, such as an adult somatic cell, by forcing the
expression of certain genes.
[0065] As used herein, the term "embryonic stem cells (ESCs)," also
commonly abbreviated as ES cells, refers to cells that are
pluripotent and derived from the inner cell mass of the blastocyst,
an early-stage embryo. For purpose of the present invention, the
term "ESCs" is used broadly sometimes to encompass the embryonic
germ cells as well.
[0066] As used herein, the term "induced pluripotent stem cells
(iPSCs)," also commonly abbreviated as iPS cells, refers to a type
of pluripotent stem cells artificially derived from a normally
non-pluripotent cell, such as an adult somatic cell, by inducing a
"forced" expression of certain genes.
[0067] As used herein, the term "precursor cell" encompasses any
cells that can be used in methods described herein, through which
one or more precursor cells acquire the ability to renew itself or
differentiate into one or more specialized cell types. In some
embodiments, a precursor cell is pluripotent or has the capacity to
becoming pluripotent. In some embodiments, the precursor cells are
subjected to the treatment of external factors (e.g., growth
factors) to acquire pluripotency. In some embodiments, a precursor
cell can be a totipotent (or omnipotent) stem cell; a pluripotent
stem cell (induced or non-induced); a multipotent stem cell; an
oligopotent stem cells and a unipotent stem cell. In some
embodiments, a precursor cell can be from an embryo, an infant, a
child, or an adult. In some embodiments, a precursor cell can be a
somatic cell subject to treatment such that pluripotency is
conferred via genetic manipulation or protein/peptide
treatment.
[0068] In developmental biology, cellular differentiation is the
process by which a less specialized cell becomes a more specialized
cell type. As used herein, the term "directed differentiation"
describes a process through which a less specialized cell becomes a
particular specialized target cell type. The particularity of the
specialized target cell type can be determined by any applicable
methods that can be used to define or alter the destiny of the
initial cell. Exemplary methods include but are not limited to
genetic manipulation, chemical treatment, protein treatment, and
nucleic acid treatment.
[0069] As used herein, the term "cellular constituents" are
individual genes, proteins, mRNA expressing genes, and/or any other
variable cellular component or protein activities such as the
degree of protein modification (e.g., phosphorylation), for
example, that is typically measured in biological experiments
(e.g., by microarray or immunohistochemistry) by those skilled in
the art. Significant discoveries relating to the complex networks
of biochemical processes underlying living systems, common human
diseases, and gene discovery and structure determination can now be
attributed to the application of cellular constituent abundance
data as part of the research process. Cellular constituent
abundance data can help to identify biomarkers, discriminate
disease subtypes and identify mechanisms of toxicity.
[0070] As used herein, the term "organoid" is used to mean a
3-dimensional growth of mammalian cells in culture that retains
characteristics of the tissue in vivo, e.g. prolonged tissue
expansion with proliferation, multilineage differentiation,
recapitulation of cellular and tissue ultrastructure, etc.
DETAILED DESCRIPTION OF THE INVENTION
[0071] Directed differentiation of human pluripotent stem cells
(hPSCs), which include embryonic (hESCs) and induced (iPSCs), is
one of the most efficient approaches to achieving differentiation
of a cell or tissue of interest (see, e.g., Spence J R, et al.,
Nature. 2011 Feb. 3; 470(7332):105-9; D'Amour K A, et al., Nat
Biotechnol. 2005 Oct. 28; 23(12):1534-41; Kroon E, et al., Nat
Biotechnol. 2008 Feb. 20; 26(4):443-52; Si-Tayeb K, et al.,
Hepatology. 2009 Oct. 1; 51(1):297-305; Wong A P, et al., Nat
Biotechnol. 2012 Aug. 26). Using this approach, differentiation of
hPSCs into lung lineages has been achieved using diverse
methodology with varying degrees of success (see, e.g., Wong A P,
et al., Nat Biotechnol. 2012 Aug. 26; Huang S X L, et al., Nat
Biotechnol; 2013 Dec. 1; 1-11; Firth A L, et al., Proceedings of
the National Academy of Sciences. 2014 Apr. 29; 111(17):E1723-30;
Mou H, et al., Cell Stem Cell. 2012 Apr. 6; 10(4):385-97; Ghaedi M,
et al., J. Clin. Invest. 2013 Nov. 1; 123(11):4950-62; Kadzik R S,
et al., Cell Stem Cell. 2012 Apr. 6; 10(4):355-61; Longmire T A, et
al., Cell Stem Cell. 2012 Apr. 6; 10(4):398-411).
[0072] Thus far, the majority of efforts to differentiate lung
lineages from hPSCs have focused on using 2-dimensional (2D)
monolayer cultures. Several recent advances in generating
3-dimensional (3D) organ-like tissues, called "organoids", have
been reported (see, e.g., Spence J R, et al., Nature. 2011 Feb. 3;
470(7332):105-9; Lancaster M A, et al., Nature. 2013 Sep. 19;
501(7467):373-9; Takebe T, et al., Nature. 2013 Jul. 25;
499(7459):481-4; Nakano T, et al., Cell Stem Cell. 2012 Jun. 14;
10(6):771-85; Meyer J S, et al., Stem Cells. 2011 Aug.;
29(8):1206-18; McCracken K W, et al., Nature; 2014 Oct. 29; :1-19).
Such 3D models offer several advantages; they often possess
structural organization similar to the native organ, cell types
from multiple germ layers (for example, mesoderm and endoderm (see,
e.g., Spence J R, et al., Nature. 2011 Feb. 3; 470(7332):105-9;
McCracken K W, et al., Nature; 2014 Oct. 29; :1-19; Wells J M, et
al., Development. 2014 February; 141(4):752-60. PMCID: PMC3912826),
and multiple cellular lineages making them a physiologically
complex model to study developmental processes, tissue homeostasis
and pathological conditions in vitro.
[0073] Previous work has demonstrated that activation of FGF and
WNT signaling synergistically drives CDX2+ intestinal lineage
commitment in hPSC-derived endoderm and also drives "morphogenesis
in a dish", where the 2D tissue self-organizes into 3D spheroids
comprised of mesenchymal and polarized epithelial layers that
detach from the adherent cell layer (see, e.g., Spence J R, et al.,
Nature. 2011 Feb. 3; 470(7332):105-9). It has also been
demonstrated that inhibition of BMP and TGF.beta. signaling is able
to drive tissue into a SOX2+ foregut lineage (see, e.g., McCracken
K W, et al., Nature; 2014 Oct. 29; :1-19; Green M D, et al., Nat
Biotechnol; 2011 Feb. 27; :1-7).
[0074] Experiments conducted during the course of developing
embodiments for the present invention demonstrated that
simultaneous stimulation of WNT and FGF signaling while inhibiting
BMP/TGF.beta. signaling pathways in hPSC-derived endoderm cultures
prevents intestinal lineage commitment, and instead, favors a SOX2+
anterior foregut fate while also robustly generating SOX2+ anterior
foregut 3D spheroid structures.
[0075] In order to further restrict foregut spheroids to the lung
lineage, such experiments additionally focused on manipulating FGF
and HH signaling. In the mouse, high levels of Fgf signaling have
been shown to induce Shh expression in the lung endoderm (see,
e.g., Rankin S A, et al., J Cell Biochem. 2014 Mar. 19; Hebrok M,
et al., Genes & Development. 1998; Morrisey E E, et al.,
Developmental Cell. Elsevier Inc; 2010 Jan. 19; 18(1):8-23) which
is accompanied by induction of the Nkx2.1+ lung progenitor field
(see, e.g., Hebrok M, et al., Genes & Development. 1998; Serls
A E; Development. 2004 Dec. 2; 132(1):35-47). Shh then signals from
the endoderm to the mesoderm, and mutations in Shh, Gli2 or Gli3
lead to perturbed lung development, with Gli2/Gli3 double knockout
mice showing lung agenesis (see, e.g., Motoyama J, et al., Nat
Genet. 1998 September; 20(1):54-7; Li Y, et al., Developmental
Biology. 2004 Jun. 1; 270(1):214-31; Bellusci S, et al.,
Development. 1997 January; 124(1):53-63).
[0076] Experiments conducted during the course of developing
embodiments for the present invention demonstrated that FGF2
induces NKX2.1, PAX8, and SHH in human foregut endoderm cultures.
By using pharmacological inhibitors of FGF and HH signaling SHH was
shown to be required for NKX2.1 expression downstream of FGF2, and
that FGF2 also induces PAX8 independently of HH signaling. These
observations suggest a paradigm where FGF.sup.Lo/HH.sup.Hi
conditions preferentially induce PAX8.sup.Lo/NKX2.1.sup.Hi lung
progenitors and FGF.sup.Hi/HH.sup.Lo conditions favor a
PAX8.sup.Hi/NKX2.1.sup.Lo fate. Given that Pax8 is required for
thyroid development, experiments were conducted focusing on
defining the most robust conditions to induce NKX2.1 while
minimizing PAX8 expression (see, e.g., Li Y, et al., Developmental
Biology. 2004 Jun. 1; 270(1):214-31; Kimura S, et al., Genes Dev.
Jan. 1; 10(1):60-927; Yuan B, et al., Dev. Dyn. 2000 February;
217(2):180-90; Narumi S, et al., Eur. J. Endocrinol. 2012 November;
167(5):625-32; Vilain C, et al., J. Clin. Endocrinol. Metab. 2001
Jan.; 86(1):234-8; Mansouri A, et al., Nat Genet. 1998 May;
19(1):87-90; Kusakabe T, et al., Mol. Endocrinol. 2006 August;
20(8):1796-809; Carre A, et al., Hum. Mol. Genet. 2009 Jun. 15;
18(12):2266-76). By applying HH.sup.Hi conditions during generation
of foregut spheroids NKX2.1 expression was shown to be enhanced in
foregut spheroids and was shown to subsequently expand spheroids in
media containing FGF10, allowing them to grow into organoids.
Organoids persisted in culture for over 100 days and developed
well-organized proximal-like airway epithelial structures that had
many cell types found in the proximal lung epithelium, including
basal and ciliated cells along with rare club cells. Moreover,
proximal airway structures were often surrounded by smooth muscle
actin (SMA) positive mesenchymal tissue. Organoids also possessed
distal-like epithelial cells that co-expressed progenitor markers,
SFTPC/SOX9 and HOPX/SOX9, consistent with early bipotent alveolar
progenitor cells seen in mice (see, e.g., Desai T J, et al.,
Nature. 2014 Feb. 5; Treutlein B, et al., Nature. 2014 May 15;
509(7500):371-5). To support the idea that organoids may be more
similar to a developing lung with abundant progenitor cells,
RNA-sequencing was used to compare the global transcriptional
profile of organoids to the human fetal and adult lung,
undifferentiated hESCs and definitive endoderm. Principal component
analysis, hierarchical clustering and Spearman's correlation all
showed that organoids have striking similarity to the human fetal
lung.
[0077] Taken together, such experiments demonstrate an efficient
and robust in vitro system to generate complex, ventral-anterior
foregut spheroid tissue formation, 3-dimensional lung tissue, and
lung organoid tissue that are immature/fetal in nature.
[0078] In some embodiments, an important step is to obtain stem
cells that are pluripotent or can be induced to become pluripotent.
In some embodiments, pluripotent stem cells are derived from
embryonic stem cells, which are in turn derived from totipotent
cells of the early mammalian embryo and are capable of unlimited,
undifferentiated proliferation in vitro. Embryonic stem cells are
pluripotent stem cells derived from the inner cell mass of the
blastocyst, an early-stage embryo. Methods for deriving embryonic
stem cells from blastocytes are well known in the art. For example,
three cell lines (H1, H13, and H14) have a normal XY karyotype, and
two cell lines (H7 and H9) have a normal XX karyotype.
[0079] Additional stem cells that can be used in embodiments in
accordance with the present invention include but are not limited
to those provided by or described in the database hosted by the
National Stem Cell Bank (NSCB), Human Embryonic Stem Cell Research
Center at the University of California, San Francisco (UCSF); WISC
cell Bank at the Wi Cell Research Institute; the University of
Wisconsin Stem Cell and Regenerative Medicine Center (UW-SCRMC);
Novocell, Inc. (San Diego, Calif.); Cellartis AB (Goteborg,
Sweden); ES Cell International Pte Ltd (Singapore); Technion at the
Israel Institute of Technology (Haifa, Israel); and the Stem Cell
Database hosted by Princeton University and the University of
Pennsylvania. Indeed, embryonic stem cells that can be used in
embodiments in accordance with the present invention include but
are not limited to SA01 (SA001); SA02 (SA002); ES01 (HES-1); ES02
(HES-2); ES03 (HES-3); ES04 (HES-4); ES05 (HES-5); ES06 (HES-6);
BG01 (BGN-01); BG02 (BGN-02); BG03 (BGN-03); TE03 (13); TE04 (14);
TE06 (16); UC01 (HSF1); UC06 (HSF6); WA01 (H1); WA07 (H7); WA09
(H9); WA13 (H13); WA14 (H14).
[0080] In some embodiments, the stem cells are further modified to
incorporate additional properties. Exemplary modified cell lines
include but not limited to H1 OCT4-EGFP; H9 Cre-LoxP; H9
hNanog-pGZ; H9 hOct4-pGZ; H9 in GFPhES; and H9 Syn-GFP.
[0081] More details on embryonic stem cells can be found in, for
example, Thomson et al., 1998, Science 282 (5391): 1145-1147;
Andrews et al., 2005, Biochem Soc Trans 33:1526-1530; Martin 1980,
Science 209 (4458):768-776; Evans and Kaufman, 1981, Nature
292(5819): 154-156; Klimanskaya et al., 2005, Lancet 365 (9471):
1636-1641).
[0082] Alternative, pluripotent stem cells can be derived from
embryonic germ cells (EGCs), which are the cells that give rise to
the gametes of organisms that reproduce sexually. EGCs are derived
from primordial germ cells found in the gonadal ridge of a late
embryo, have many of the properties of embryonic stem cells. The
primordial germ cells in an embryo develop into stem cells that in
an adult generate the reproductive gametes (sperm or eggs). In mice
and humans it is possible to grow embryonic germ cells in tissue
culture under appropriate conditions. Both EGCs and ESCs are
pluripotent. For purpose of the present invention, the term "ESCs"
is used broadly sometimes to encompass EGCs.
[0083] In some embodiments, iPSCs are derived by transfection of
certain stem cell-associated genes into non-pluripotent cells, such
as adult fibroblasts. Transfection is typically achieved through
viral vectors, such as retroviruses. Transfected genes include the
master transcriptional regulators Oct-3/4 (Pouf51) and Sox2,
although it is suggested that other genes enhance the efficiency of
induction. After 3-4 weeks, small numbers of transfected cells
begin to become morphologically and biochemically similar to
pluripotent stem cells, and are typically isolated through
morphological selection, doubling time, or through a reporter gene
and antibiotic selection. As used herein, iPSCs include but are not
limited to first generation iPSCs, second generation iPSCs in mice,
and human induced pluripotent stem cells. In some embodiments, a
retroviral system is used to transform human fibroblasts into
pluripotent stem cells using four pivotal genes: Oct3/4, Sox2,
Klf4, and c-Myc. In alternative embodiments, a lentiviral system is
used to transform somatic cells with OCT4, SOX2, NANOG, and LIN28.
Genes whose expression are induced in iPSCs include but are not
limited to Oct-3/4 (e.g., Pou5fl); certain members of the Sox gene
family (e.g., Sox1, Sox2, Sox3, and Sox15); certain members of the
Klf family (e.g., Klf1, Klf2, Klf4, and Klf5), certain members of
the Myc family (e.g., C-myc, L-myc, and N-myc), Nanog, and
LIN28.
[0084] More details on induced pluripotent stem cells can be found
in, for example, Kaji et al., 2009, Nature 458:771-775; Woltjen et
al., 2009, Nature 458:766-770; Okita et al., 2008, Science
322(5903):949-953; Stadtfeld et al., 2008, Science
322(5903):945-949; and Zhou et al., 2009, Cell Stem Cell
4(5):381-384.
[0085] In some embodiments, examples of iPS cell lines include but
not limited to iPS-DF19-9; iPS-DF19-9; iPS-DF4-3; iPS-DF6-9;
iPS(Foreskin); iPS(IMR90); and iPS(IMR90).
[0086] The lungs of mammals including those of humans, have a soft,
spongelike texture and are honeycombed with epithelium, having a
much larger surface area in total than the outer surface area of
the lung itself.
[0087] Breathing is largely driven by the muscular diaphragm at the
bottom of the thorax. Contraction of the diaphragm pulls the bottom
of the cavity in which the lung is enclosed downward, increasing
volume and thus decreasing pressure, causing air to flow into the
airways. Air enters through the oral and nasal cavities; it flows
through the pharynx, then the larynx and into the trachea, which
branches out into the main bronchi and then subsequent divisions.
During normal breathing, expiration is passive and no muscles are
contracted (the diaphragm relaxes). The rib cage itself is also
able to expand and contract to some degree through the use of the
intercostal muscles, together with the action of other respiratory
and accessory respiratory muscles. As a result, air is transported
into or expelled out of the lungs.
[0088] In humans, the trachea divides into two main bronchi that
enter the roots of the lungs. The bronchi continue to divide within
the lung, and after multiple divisions, give rise to bronchioles.
The bronchial tree continues branching until it reaches the level
of terminal bronchioles, which lead to alveolar sacs. Alveolar
sacs, are made up of clusters of alveoli, like individual grapes
within a bunch. The individual alveoli are tightly wrapped in blood
vessels and it is here that gas exchange actually occurs.
Deoxygenated blood from the heart is pumped through the pulmonary
artery to the lungs, where oxygen diffuses into blood and is
exchanged for carbon dioxide in the haemoglobin of the
erythrocytes. The oxygen-rich blood returns to the heart via the
pulmonary veins to be pumped back into systemic circulation.
[0089] Human lungs are located in two cavities on either side of
the heart. Though similar in appearance, the two are not identical.
Both are separated into lobes by fissures, with three lobes on the
right and two on the left. The lobes are further divided into
segments and then into lobules, hexagonal divisions of the lungs
that are the smallest subdivision visible to the naked eye. The
connective tissue that divides lobules is often blackened in
smokers. The medial border of the right lung is nearly vertical,
while the left lung contains a cardiac notch. The cardiac notch is
a concave impression molded to accommodate the shape of the
heart.
[0090] Each lobe is surrounded by a pleural cavity, which consists
of two pleurae. The parietal pleura lies against the rib cage, and
the visceral pleura lies on the surface of the lungs. In between
the pleura is pleural fluid. The pleural cavity helps to lubricate
the lungs, as well as providing surface tension to keep the lung
surface in contact with the rib cage.
[0091] Lungs are to a certain extent "overbuilt" and have a
tremendous reserve volume as compared to the oxygen exchange
requirements when at rest. Such excess capacity is one of the
reasons that individuals can smoke for years without having a
noticeable decrease in lung function while still or moving slowly;
in situations like these only a small portion of the lungs are
actually perfused with blood for gas exchange. Destruction of too
many alveoli over time leads to the condition emphysema, which is
associated with extreme shortness of breath. As oxygen requirements
increase due to exercise, a greater volume of the lungs is
perfused, allowing the body to match its CO.sub.2/O.sub.2 exchange
requirements. Additionally, due to the excess capacity, it is
possible for humans to live with only one lung, with the one
compensating for the other's loss.
[0092] The environment of the lung is very moist, which makes it
hospitable for bacteria. Many respiratory illnesses are the result
of bacterial or viral infection of the lungs. Inflammation of the
lungs is known as pneumonia; inflammation of the pleura surrounding
the lungs is known as pleurisy.
[0093] Vital capacity is the maximum volume of air that a person
can exhale after maximum inhalation; it can be measured with a
spirometer. In combination with other physiological measurements,
the vital capacity can help make a diagnosis of underlying lung
disease.
[0094] The lung parenchyma is strictly used to refer solely to
alveolar tissue with respiratory bronchioles, alveolar ducts and
terminal bronchioles. However, it often includes any form of lung
tissue, also including bronchioles, bronchi, blood vessels and lung
interstitium.
[0095] Following gastrulation (embryonic day E7.5 in mice), the
definitive endoderm undergoes complex morphogenetic movements that
ultimately lead to the formation of the primitive gut tube. The
foregut represents the most anterior (cranial) region of this tube,
while the midgut and hindgut are located at progressively more
posterior regions, towards the caudal end of the embryo (see, e.g.,
Wells, et al., Annu. Rev. Cell Dev. Biol. 15, 393-410).
Transcription factor genes such as Foxa1, Foxa2, Gata4 and Gata6,
which are expressed early in the endoderm, are crucial for the
survival, differentiation and morphogenesis of the foregut (see,
e.g., Kuo, et al., Genes Dev. 11, 1048-1060; Morrisey, et al.,
Genes Dev. 12, 3579-3590; Ang, et al., Cell 78, 561-574; Wan, et
al., J. Biol. Chem. 280, 13809-13816). By E8.0-9.5, the local
expression of transcription factors along the anteroposterior (AP)
axis of the gut endoderm marks organ-specific domains (or fields).
For example, the homeodomain protein gene Nkx2.1 [also known as
thyroid transcription factor 1 (Titf1) or T/EBP] is expressed in
the thyroid and respiratory fields (see, e.g., Kimura, et al.,
Genes Dev. 10, 60-69), Hex (hematopoietically expressed homeobox)
is expressed in the thyroid and liver fields (see, e.g., Martinez
Barbera, et al., Development 127, 2433-2445), and the Pdx1
(pancreas-duodenal-associated homeobox gene) is expressed in the
pancreatic and duodenal fields (see, e.g., Offield, et al.,
Development 122, 983-995). In addition, morphogenetic movements
foster dynamic interactions between the endoderm and neighboring
structures, such as the heart, notochord or the septum transversum
(the mesodermal cells that give rise to the diaphragm). Exposure of
the endoderm to diffusible signals from these structures at crucial
developmental windows is essential for endodermal cell fate
specification (see, e.g., Kumar and Melton, Curr. Opin. Genet. Dev.
13, 401-407; Bort, et al., Development 131, 797-80).
[0096] Fibroblast growth factor 4 (Fgf4), bone morphogenetic
protein 2 (Bmp2) and retinoic acid (RA) are among the signals that
confer AP identity to the early endoderm. They render the endoderm
competent to respond to signals from the adjacent mesoderm or from
nearby structures to initiate morphogenesis (see, e.g., Tiso, eta
al., Mech. Dev. 118, 29-37; Stafford and Prince, Curr. Biol. 12,
1215-1220; Wells and Melton, Development 127, 1563-1572). In
zebrafish, disrupted RA signaling during gastrulation results in
the loss of liver and pancreatic (posterior) fates, while thyroid
and pharynx (anterior) fates remain unaltered. Conversely, excess
RA induces hepatic and pancreatic cell fates at more anterior
domains (see, e.g., Stafford and Prince; Curr. Biol. 12,
1215-1220). In mice and rats, RA signaling initiates soon after
gastrulation (see, e.g., Rossant, et al., Genes Dev. 5, 1333-1344),
but does not seem to be as crucial for foregut AP identity as it is
in the zebrafish.
[0097] The present invention provides methods for directing the
differentiation of definitive endoderm (DE) into lung organoids in
vitro.
[0098] In some embodiments, PSCs, such as ESCs and iPSCs, undergo
directed differentiation in a step-wise manner first into
definitive endoderm (DE), then into ventral-anterior foregut
spheroid tissue (e.g., SOX2+ anterior foregut 3D spheroid
structures), then into 3-dimensional lung tissue, and then into
lung organoid tissue.
[0099] As such, in some embodiments, methods are provided for the
directed differentiation of pluriopotent cells (e.g., iPSCs or
ESCs) into definitive endoderm, and the obtaining of such
definitive endoderm. In some embodiments, methods are provided for
the directed differentiation of the obtained definitive endoderm
into ventral-anterior foregut spheroid tissue, and obtaining of
such ventral-anterior foregut spheroid tissue. In some embodiments,
methods are provided for the directed differentiation of the
obtained ventral-anterior foregut spheroid tissue into
3-dimensional lung tissue, and the obtaining of such 3-dimensional
lung tissue. In some embodiments, methods are provided for the
directed differentiation of the obtained 3-dimensional lung tissue
into lung organoid tissue, and the obtaining of such lung organoid
tissue.
[0100] Such methods are not limited to a particular manner of
accomplishing the directed differentiation of PSCs into definitive
endoderm. Indeed, any method for producing definitive endoderm from
pluripotent cells (e.g., iPSCs or ESCs) is applicable to the
methods described herein. In some embodiments, pluripotent cells
are derived from a morula. In some embodiments, pluripotent stem
cells are stem cells. Stem cells used in these methods can include,
but are not limited to, embryonic stem cells. Embryonic stem cells
can be derived from the embryonic inner cell mass or from the
embryonic gonadal ridges. Embryonic stem cells or germ cells can
originate from a variety of animal species including, but not
limited to, various mammalian species including humans. In some
embodiments, human embryonic stem cells are used to produce
definitive endoderm. In some embodiments, human embryonic germ
cells are used to produce definitive endoderm. In some embodiments,
iPSCs are used to produce definitive endoderm.
[0101] In some embodiments, one or more growth factors are used in
the differentiation process from pluripotent stem cells to DE
cells. The one or more growth factors used in the differentiation
process can include growth factors from the TGF-.beta. superfamily.
In such embodiments, the one or more growth factors comprise the
Nodal/Activin and/or the BMP subgroups of the TGF-.beta.
superfamily of growth factors. In some embodiments, the one or more
growth factors are selected from the group consisting of Nodal,
Activin A, Activin B, BMP4, Wnt3a or combinations of any of these
growth factors.
[0102] In some embodiments, the embryonic stem cells or germ cells
and iPSCs are treated with the one or more growth factors for 6 or
more hours; 12 or more hours; 18 or more hours; 24 or more hours;
36 or more hours; 48 or more hours; 60 or more hours; 72 or more
hours; 84 or more hours; 96 or more hours; 120 or more hours; 150
or more hours; 180 or more hours; or 240 or more hours.
[0103] In some embodiments, the embryonic stem cells or germ cells
and iPSCs are treated with the one or more growth factors at a
concentration of 10 ng/ml or higher; 20 ng/ml or higher; 50 ng/ml
or higher; 75 ng/ml or higher; 100 ng/ml or higher; 120 ng/ml or
higher; 150 ng/ml or higher; 200 ng/ml or higher; 500 ng/ml or
higher; 1,000 ng/ml or higher; 1,200 ng/ml or higher; 1,500 ng/ml
or higher; 2,000 ng/ml or higher; 5,000 ng/ml or higher; 7,000
ng/ml or higher; 10,000 ng/ml or higher; or 15,000 ng/ml or higher.
In some embodiments, concentration of the growth factor is
maintained at a constant level throughout the treatment. In other
embodiments, concentration of the growth factor is varied during
the course of the treatment. In some embodiments, the growth factor
is suspended in media that include fetal bovine serine (FBS) with
varying HyClone concentrations. One of skill in the art would
understand that the regimen described herein is applicable to any
known growth factors, alone or in combination. When two or more
growth factors are used, the concentration of each growth factor
may be varied independently.
[0104] In some embodiments, populations of cells enriched in
definitive endoderm cells are used. In some embodiments, the
definitive endoderm cells are isolated or substantially purified.
In some embodiments, the isolated or substantially purified
definitive endoderm cells express the SOX2+ marker.
[0105] Methods for enriching a cell population with definitive
endoderm are also contemplated. In some embodiments, definitive
endoderm cells can be isolated or substantially purified from a
mixed cell population by contacting the cells with a reagent that
binds to a molecule that is present on the surface of definitive
endoderm cells but which is not present on the surface of other
cells in the mixed cell population, and then isolating the cells
bound to the reagent.
[0106] Additional methods for obtaining or creating DE cells that
can be used in the present invention include but are not limited to
those described in U.S. Pat. Nos. 7,510,876; 7,326,572; Kubol et
al., 2004, Development 131:1651-1662; D'Amour et al., 2005, Nature
Biotechnology 23:1534-1541; and Ang et al., 1993, Development
119:1301-1315.
[0107] In some embodiments, directed differentiation toward
ventral-anterior foregut spheroid tissue, 3-dimensional lung
tissue, and lung organoid tissue is achieved by selectively
activating or inhibiting certain signaling pathways in the iPSCs
and/or DE cells. In some embodiments, the activated and/or
inhibited signaling pathways are those active in lung development,
including but not limited to the BMP signaling pathway, the
TGF.beta. signaling pathway, the Wnt signaling pathway, the FGF
signaling pathway, and the Hedgehog signaling pathway in a
step-wise manner.
[0108] In some embodiments, directed differentiation of definitive
endoderm into lung organoid tissue is accomplished first through
directed differentiation of definitive endoderm into
ventral-anterior foregut spheroid tissue, then directed
differentiation of the ventral-anterior foregut spheroid tissue
into 3-dimensional lung tissue, and then directed differentiation
of the 3-dimensional lung tissue into lung organoid tissue.
[0109] Such techniques are not limited to a particular manner of
inducing formation of ventral-anterior foregut spheroid tissue from
definitive endoderm. In some embodiments, inducing formation of
ventral-anterior foregut spheroid tissue from definitive endoderm
is accomplished through selectively activating the Wnt signaling
pathway and the FGF signaling pathway, and inhibiting the BMP
signaling pathway, and the TGF.beta. signaling pathway in the DE
cells. In some embodiments, activating and/or inhibiting one or
more signaling pathways within the definitive endoderm cells
comprises culturing the definitive endoderm cells with a Wnt
signaling pathway agonist, a FGF signaling pathway agonist, a BMP
signaling pathway inhibitor, and a TGF.beta. signaling pathway
inhibitor. In some embodiments, activating and/or inhibiting one or
more signaling pathways within the definitive endoderm cells
comprises culturing the definitive endoderm cells with CHIR99021,
FGF4, Noggin, and SB431542.
[0110] Such techniques are not limited to a particular manner of
inducing formation of 3-dimensional lung tissue from the
ventral-anterior foregut spheroid tissue. In some embodiments,
inducing formation of 3-dimensional lung tissue from the
ventral-anterior foregut spheroid tissue occurs through activating
the Hedgehog signaling pathway within the ventral-anterior foregut
spheroid tissue. Such methods are not limited to a particular
manner of activating the Hedgehog signaling pathway within the
obtained ventral-anterior foregut spheroid tissue. In some
embodiments, culturing the obtained ventral-anterior foregut
spheroid tissue occurs through activating the Hedgehog signaling
pathway occurs through culturing the obtained ventral-anterior
foregut spheroid tissue with a small molecule or agonist that
activates the Hedgehog signaling pathway. In some embodiments, the
small molecule or agonist that activates the Hedgehog signaling
pathway is smoothened agonist (SAG).
[0111] Such techniques are not limited to a particular manner of
inducing formation of lung organoid tissue from the 3-dimensional
lung tissue. In some embodiments, inducing formation of lung
organoid tissue from the 3-dimensional lung tissue occurs through
activating the FGF pathway within the 3-dimensional lung tissue.
Such methods are not limited to a particular manner of activating
the FGF signaling pathway within the obtained 3-dimensional lung
tissue. In some embodiments, culturing the obtained 3-dimensional
lung tissue through activating the FGF signaling pathway occurs
through culturing the obtained 3-dimensional lung tissue with a
small molecule or agonist that activates the FGF signaling pathway.
In some embodiments, the small molecule or agonist that activates
the FGF signaling pathway is selected from FGF1, FGF2, FGF3, FGF4,
FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18,
FGF19, FGF20, FGF21, FGF22, and FGF23. In some embodiments, the
small molecule or agonist that activates the FGF signaling pathway
is FGF10.
[0112] In some embodiments, the obtained lung organoid tissue
comprises upper airway-like epithelium with basal cells, immature
ciliated cells surrounded by smooth muscle and myofibroblasts,
and/or alveolar-like cells.
[0113] In some embodiments, selective inhibiting of the BMP
signaling pathway is accomplished with a small molecule or
antagonist that inhibits the BMP signaling pathway. BMPs bind as a
dimeric ligand to a receptor complex consisting of two different
receptor serine/threonine kinases, type I and type II receptors.
The type II receptor phosphorylates the type I receptor, resulting
in the activation of this receptor kinase. The type I receptor
subsequently phosphorylates specific receptor substrates (SMAD),
resulting in a signal transduction pathway leading to
transcriptional activity.
[0114] A BMP inhibitor (e.g., a small molecule or antagonist that
inhibits the BMP signaling pathway) is defined as an agent that
binds to a BMP molecule to form a complex wherein the BMP activity
is neutralized, for example by preventing or inhibiting the binding
of the BMP molecule to a BMP receptor. Alternatively, said
inhibitor is an agent that acts as an antagonist or reverse
agonist. This type of inhibitor binds with a BMP receptor and
prevents binding of a BMP to said receptor. An example of a latter
agent is an antibody that binds a BMP receptor and prevents binding
of BMP to the antibody-bound receptor.
[0115] A BMP inhibitor may be added to iPSCs and/or DE cells for
purposes of directed differentiation of such cells toward lung
organoids. In some embodiments, the amount of BMP inhibitor added
to iPSCs and/or DE cells for purposes of directed differentiation
of such cells toward lung organoids is any amount effective to
inhibit a BMP-dependent activity in such cells to at most 90%, more
preferred at most 80%, more preferred at most 70%, more preferred
at most 50%, more preferred at most 30%, more preferred at most
10%, more preferred 0%, relative to a level of a BMP activity in
the absence of said inhibitor, as assessed in the same cell type.
As is known to a skilled person, a BMP activity can be determined
by measuring the transcriptional activity of BMP, for example as
exemplified in Zilberberg et al., 2007. BMC Cell Biol. 8:41.
[0116] Several classes of natural BMP-binding proteins are known,
including Noggin (Peprotech), Chordin and chordin-like proteins
(R&D systems) comprising chordin domains, Follistatin and
follistatin-related proteins (R&D systems) comprising a
follistatin domain, DAN and DAN-like proteins (R&D systems)
comprising a DAN cysteine-knot domain, sclerostin/SOST (R&D
systems), decorin (R&D systems), and alpha-2 macroglobulin
(R&D systems).
[0117] In some embodiments, the BMP inhibitor is Noggin ("Nog"). In
some embodiments, the amount of Noggin added to the iPSCs and/or DE
cells for purposes of directed differentiation of such cells toward
lung organoids is, for example, at a concentration of at least 10
ng/ml, more preferred at least 20 ng/ml, more preferred at least 50
ng/ml, more preferred at least 100 ng/ml. A still more preferred
concentration is approximately 100 ng/ml or exactly 100 ng/ml.
[0118] In some embodiments, selective activation of the Wnt
signaling pathway is accomplished with a Wnt agonist ("W").
[0119] The Wnt signalling pathway is defined by a series of events
that occur when a Wnt protein binds to a cell-surface receptor of a
Frizzled receptor family member. This results in the activation of
Dishevelled family proteins which inhibit a complex of proteins
that includes axin, GSK-3, and the protein APC to degrade
intracellular .beta.-catenin. The resulting enriched nuclear
.beta.-catenin enhances transcription by TCF/LEF family
transcription factors.
[0120] A Wnt agonist (e.g., a small molecule or agonist that
activates the Wnt signaling pathway) is defined as an agent that
activates TCF/LEF-mediated transcription in a cell. Wnt agonists
are therefore selected from true Wnt agonists that bind and
activate a Frizzled receptor family member including any and all of
the Wnt family proteins, an inhibitor of intracellular
.beta.-catenin degradation, and activators of TCF/LEF. Said Wnt
agonist is added to the iPSCs and/or DE cells for purposes of
directed differentiation of such cells toward lung organoids in an
amount effective to stimulate a Wnt activity in a cell by at least
10%, more preferred at least 20%, more preferred at least 30%, more
preferred at least 50%, more preferred at least 70%, more preferred
at least 90%, more preferred at least 100%, relative to a level of
said Wnt activity in the absence of said molecule, as assessed in
the same cell type. As is known to a skilled person, a Wnt activity
can be determined by measuring the transcriptional activity of Wnt,
for example by pTOPFLASH and pFOPFLASH Tcfluciferase reporter
constructs (see, e.g., Korinek et al., 1997. Science
275:1784-1787).
[0121] A Wnt agonist may comprise a secreted glycoprotein including
Wnt-1/Int-1; Wnt-2/Irp (Int-1-related Protein); Wnt-2b/13;
Wnt-3/Int-4; Wnt-3a (R&D systems); Wnt-4; Wnt-5a; Wnt-5b; Wnt-6
(Kirikoshi H et al. 2001. Biochem Biophys Res Com 283: 798-805);
Wnt-7a (R&D systems); Wnt-7b; Wnt-8a/8d; Wnt-8b; Wnt-9a/14;
Wnt-9b/14b/15; Wnt-10a; Wnt-10b/12; Wnt-11; and Wnt-16. An overview
of human Wnt proteins is provided in "THE WNT FAMILY OF SECRETED
PROTEINS", R&D Systems Catalog, 2004.
[0122] Further Wnt agonists include the R-spondin family of
secreted proteins, which is implicated in the activation and
regulation of Wnt signaling pathway and which is comprised of 4
members (R-spondin 1 (NU206, Nuvelo, San Carlos, Calif.), R-spondin
2 ((R&D systems), R-spondin 3, and R-spondin-4); and Norrin
(also called Norrie Disease Protein or NDP) (R&D systems),
which is a secreted regulatory protein that functions like a Wnt
protein in that it binds with high affinity to the Frizzled-4
receptor and induces activation of the Wnt signaling pathway
(Kestutis Planutis et al. (2007) BMC Cell Biol. 8: 12).
[0123] Compounds that mimic the activity of R-spondin may be used
as Wnt agonists of the invention. It has recently been found that
R-spondin interacts with Lgr5. Thus, Lgr5 agonists such as
agonistic anti-Lgr5 antibodies are examples of Wnt agonists that
may be used in the invention.
[0124] A small-molecule agonist of the Wnt signaling pathway, an
aminopyrimidine derivative, was identified and is also expressly
included as a Wnt agonist (Liu et al. (2005) Angew Chem Int Ed
Engl. 44, 1987-90).
[0125] Known GSK-inhibitors comprise small-interfering RNAs (siRNA;
Cell Signaling), lithium (Sigma), kenpaullone (Biomol
International; Leost, M. et al. (2000) Eur. J. Biochem. 267,
5983-5994), 6-Bromoindirubin-30-acetoxime (Meijer, L. et al. (2003)
Chem. Biol. 10, 1255-1266), SB 216763 and SB 415286
(Sigma-Aldrich), and FRAT-family members and FRAT-derived peptides
that prevent interaction of GSK-3 with axin. An overview is
provided by Meijer et al., (2004) Trends in Pharmacological
Sciences 25, 471-480. Methods and assays for determining a level of
GSK-3 inhibition are known to a skilled person and comprise, for
example, the methods and assay as described in Liao et al 2004,
Endocrinology, 145(6): 2941-9.
[0126] In some embodiments the Wnt agonist is a Gsk3 inhibitor. In
some embodiments, the Gsk3 inhibitor is selected from the group
consisting of CHIR 99021, CHIR 98014, BIO-acetoxime, BIO, LiCl, SB
216763, SB 415286, AR A014418, 1-Azakenpaullone, and
Bis-7-indolylmaleimide. In some embodiments the Gsk3 inhibitor is
CHIR 99021 or CHIR 98014 at a concentration of at least about 4
.mu.M to about 10 .mu.M i. In some embodiments the Gsk3 inhibitor
comprises an RNAi targeted against Gsk3.
[0127] In some embodiments, the Wnt agonist added to the iPSCs
and/or DE cells for purposes of directed differentiation of such
cells toward lung organoids is CHIR 99021. In some embodiments,
CHIR 99021 is preferably added to the iPSCs and/or DE cells for
purposes of directed differentiation of such cells toward lung
organoids at a concentration of at least 200 In some embodiments,
selective activation of the FGF signaling pathway is accomplished
with a FGF agonist ("F") (e.g., a small molecule or agonist that
activates the FGF signaling pathway).
[0128] In some embodiments, the FGF agonist added to the iPSCs
and/or DE cells for purposes of directed differentiation of such
cells toward lung organoids is able to bind to FGFR2 or FGFR4. An
FGF able to bind to FGFR2 (FGF receptor) or FGFR4 is preferably
FGF4, FGF7 or FGF10, most preferably FGF10.
[0129] FGF10 is a protein that belongs to the fibroblast growth
factor (FGF) family of proteins. FGF family members possess broad
mitogenic and cell survival activities, and are involved in a
variety of biological processes, including embryonic development,
cell growth, morphogenesis, tissue repair, tumor growth and
invasion. FGFs stimulate cells by interacting with cell surface
tyrosine kinase receptors (FGFR). Four closely related receptors
(FGFR1-FGFR4) have been identified. FGFR1-FGFR3 genes have been
shown to encode multiple isoforms, and these isoforms can be
critical in determining ligand specificity. Most FGFs bind more
than one receptor (Ornitz J Biol. Chem. 1998 Feb. 27; 273
(9):5349-57). However, FGF10 and FGF7 are unique among FGFs in that
they interact only with a specific isoform of FGFR2, designated
FGFR2b which is expressed exclusively by epithelial cells
(Igarashi, J Biol. Chem. 1998 273(21):13230-5). FGF10 is a
preferred FGF able to bind to FGFR2 or FGFR4.
[0130] Preferred concentrations for FGF10 are 20, 50, 100, 500
ng/ml, not higher than 500 ng/ml. FGF (e.g., FGF10) is preferably
added to the iPSCs and/or DE cells for purposes of directed
differentiation of such cells toward lung organoids when
required.
[0131] TGF-.beta. signaling pathway is used to describe the
downstream signaling events attributed to TGF-.beta. and TGF-.beta.
like ligands. For example, in one signaling pathway a TGF-.beta.
ligand binds to and activates a Type II TGF-.beta. receptor. The
Type II TGF-.beta. receptor recruits and forms a heterodimer with a
Type I TGF-.beta. receptor. The resulting heterodimer permits
phosphorylation of the Type I receptor, which in turn
phosphorylates and activates a member of the SMAD family of
proteins. A signaling cascade is triggered, which is well known to
those of skill in the art, and ultimately leads to control of the
expression of mediators involved in cell growth, cell
differentiation, tumorigenesis, apoptosis, and cellular
homeostasis, among others. Other TGF-.beta. signaling pathways are
also contemplated for manipulation according to the methods
described herein.
[0132] A TGF-.beta. inhibitor (e.g., a small molecule or antagonist
that inhibits the TGF-.beta. signaling pathway) refers to
inhibition of at least one of the proteins involved in the signal
transduction pathway for TGF-.beta.. It is contemplated herein that
an inhibitor of the TGF-.beta. signaling pathway can be, for
example, a TGF-.beta. receptor inhibitor (e.g., a small molecule,
an antibody, an siRNA), a TGF-.beta. sequestrant (e.g., an
antibody, a binding protein), an inhibitor of receptor
phosphorylation, an inhibitor of a SMAD protein, or a combination
of such agents.
[0133] In some embodiments, a TGF-.beta. inhibitor such as SB431542
(SB) is additionally added to the iPSCs and/or DE cells for
purposes of directed differentiation of such cells toward lung
organoids.
[0134] In some embodiments, the TGF-.beta. signaling pathway
inhibitor comprises or consists essentially of a TGF-.beta.
receptor inhibitor. One of skill in the art can easily test a
compound to determine if it inhibits TGF-.beta. receptor signaling
by assessing, for example, phosphorylation status of the receptor
or expression of downstream proteins controlled by TGF-.beta. in
cultured cells and comparing the results to cells not treated with
a TGF-.beta. receptor inhibitor. An agent is determined to be a
TGF-.beta. signaling pathway inhibitor if the level of
phosphorylation of the Type I TGF-.beta. receptor in a culture of
cells is reduced by at least 20% compared to the level of
phosphorylation of the Type I TGF-.beta. receptor in cells that are
cultured in the absence of a TGF-.beta. signaling pathway
inhibitor; preferably the level of phosphorylation is reduced by at
least 30%, at least 40%, at least 50%, at least 60%, at least 70%,
at least 80%, at least 90%, at least 95%, at least 99%, or even
100% (no phosphorylation) in the presence of a TGF-.beta. signaling
pathway inhibitor.
[0135] In some embodiments, a Hedgehog signaling pathway agonist
(e.g., a small molecule or agonist that activates the Hedgehog
signaling pathway) is additionally added to the iPSCs and/or DE
cells for purposes of directed differentiation of such cells toward
lung organoids. In some embodiments, the hedgehog signaling pathway
agonist is any compound that activates the hedgehog receptor. In
some embodiments, the hedgehog signaling pathway agonist is
smoothened agonist (SAG).
[0136] In some embodiments, ventral-anterior foregut spheroid
tissue and/or 3-dimensional lung tissue and/or lung organoid tissue
produced in vitro from the described methods can be used to screen
drugs for lung tissue uptake and mechanisms of transport. For
example, this can be done in a high throughput manner to screen for
the most readily absorbed drugs, and can augment Phase 1 clinical
trials that are done to study drug lung tissue uptake and lung
tissue toxicity. This includes pericellular and intracellular
transport mechanisms of small molecules, peptides, metabolites,
salts.
[0137] In some embodiments, ventral-anterior foregut spheroid
tissue and/or 3-dimensional lung tissue and/or lung organoid tissue
produced in vitro from the described methods can be used to
identify the molecular basis of normal human lung development.
[0138] In some embodiments, ventral-anterior foregut spheroid
tissue and/or 3-dimensional lung tissue and/or lung organoid tissue
produced in vitro from the described methods can be used to
identify the molecular basis of congenital defects affecting human
lung development.
[0139] In some embodiments, 3 ventral-anterior foregut spheroid
tissue and/or 3-dimensional lung tissue and/or lung organoid tissue
produced in vitro from the described methods can be used to correct
lung related congenital defects caused by genetic mutations. In
particular, mutation affecting human lung development can be
corrected using iPSC technology and genetically normal
ventral-anterior foregut spheroid tissue and/or 3-dimensional lung
tissue and/or lung organoid tissue produced in vitro from the
described methods. In some embodiments, ventral-anterior foregut
spheroid tissue and/or 3-dimensional lung tissue and/or lung
organoid tissue produced in vitro from the described methods can be
used to generate replacement tissue.
[0140] In some embodiments, ventral-anterior foregut spheroid
tissue and/or 3-dimensional lung tissue and/or lung organoid tissue
produced in vitro from the described methods can be used to
generate replacement lung tissue for lung related disorders.
[0141] In some embodiments, a diagnostic kit or package is
developed to include ventral-anterior foregut spheroid tissue
and/or 3-dimensional lung tissue and/or lung organoid tissue
produced in vitro from the described methods and based on one or
more of the aforementioned utilities.
EXAMPLES
[0142] The following examples are illustrative, but not limiting,
of the compounds, compositions, and methods of the present
invention. Other suitable modifications and adaptations of the
variety of conditions and parameters normally encountered in
clinical therapy and which are obvious to those skilled in the art
are within the spirit and scope of the invention.
Example 1
[0143] This example describes differentiation of hPSCs into
anterior foregut spheroids.
[0144] Efficient induction of human endoderm using ActivinA has
been described (see, e.g., Spence J R, et al., Nature. 2011 Feb. 3;
470(7332):105-9; D'Amour K A, et al., Nat Biotechnol. 2005 Oct. 28;
23(12):1534-41; Zhang M, et al., Histochem. Cell Biol. 2010
October; 134(4):327-35), and a further lineage restriction into
SOX2+ anterior foregut endoderm using inhibition of BMP and
TGF.beta. signaling has been described (see, e.g., Green M D, et
al., Nat Biotechnol. Nature Publishing Group; 2011 Feb. 27:1-7; Loh
K M, et al., Cell Stem Cell. 2014 Feb. 6; 14(2):237-52). It has
been demonstrated that inhibition of BMP signaling during
intestinal lineage induction with WNT and FGF ligands is sufficient
to inhibit intestinal CDX2 and induce SOX2+ posterior foregut
spheroids capable of giving rise to human gastric (antral)
organoids (see, e.g., McCracken K W, et al., Nature; 2014 Oct.
29:1-19). Given that the lung is derived from the anterior foregut,
experiments were conducted to define conditions to generate ventral
anterior foregut spheroids. To do this, tests were conducted to
determine if dual inhibition of BMP and TGF was able to anteriorize
cultures, as previously described (see, e.g., Green M D, et al.,
Nat Biotechnol; 2011 Feb. 27:1-7). hESCs were treated with ActivinA
(100 ng/mL) for four days to induce endoderm, followed by four days
of Noggin (NOG, 200 ng/mL) and the small molecule TGF inhibitor,
SB431542 (SB, 10 .mu.M). It was confirmed that these conditions
were able to induce robust mRNA and protein expression of SOX2,
which co-expressed with endodermal marker FOXA2, while repressing
the intestinal lineage marker CDX2 (see, FIG. 1A-C, FIG. 2A).
QRT-PCR analysis also showed that compared to controls (in which
endoderm was induced but was not exposed to NOG/SB), exposure to
NOG/SB robustly induced ventral anterior foregut genes NKX2.1 and
PAX8, while the posterior foregut transcript, PDX1 was reduced.
HHEX, which is expressed in the developing liver, biliary system
and thyroid, but is absent from the lung primordium, remained
unchanged (see, FIG. 1B). Given that NKX2.1 is expressed in the
lung and thyroid primordium, and PAX8 is expressed in the thyroid
primordium, these results suggest that 4 day ActivinA treatment
followed by a 4 day NOG/SB treatment biases the cultures towards
ventral-anterior foregut lineages.
[0145] Addition of FGF4 plus WNT3A (or Chir99021, a GSK3.beta.
inhibitor that enhances .beta.-catenin dependent WNT signaling)
promotes CDX2 intestinal lineage commitment and 3D spheroid
formation in endoderm cultures (see, e.g., Spence J R, et al.,
Nature. 2011 Feb. 3; 470(7332):105-9; Green M D, et al., Nature;
2011 Feb. 27; :1-7; Loh K M, et al., Cell Stem Cell. 2014 Feb. 6;
14(2):237-52; Xue X, et al., Gastroenterology. 2013 Jul. 13). Based
on the results in FIG. 1B-C, it was hypothesized that combining
FGF, Chir99021, NOG and SB would result in the generation of SOX2+
ventral-anterior foregut spheroids. To test this, endoderm was
generated (4 days ACTA) and either no growth factors were added
(Endoderm controls) or NOG, SB, FGF4, and Chir99021 (NOG/SB/F/Ch)
added (FIG. 1D). Addition of all four factors resulted in the
generation of 3-dimensional SOX2+, CDX2- spheroids (FIG. 1E, F).
SOX2+ spheroids also expressed the endodermal protein FOXA2, and
were epithelial, co-expressing E-Cadherin (ECAD) (FIG. 1F, FIG. 3).
In addition to SOX2, spheroids exhibited higher mRNA expression of
anterior foregut lineage markers NKX2.1 and PAX8 compared to
endoderm controls, suggesting that they are ventral-anterior
foregut spheroids (FIG. 1E), however, immunofluorescence revealed
that levels of NKX2.1 protein were just above the detection
threshold (FIG. 3). Spheroids also possess a minor population of
cells that are mesodermal in origin staining positive for Vimentin
protein (VIM) (FIG. 4). Given that neural tissues also express
NKX2.1, PAX8, SOX2, and FOXA2, and that neural induction protocols
use dual BMP and TGF.beta. inhibition, it was intended to exclude
the possibility that spheroids were neural in nature. To do this,
endoderm control cultures, foregut spheroids (ActivinA followed by
NOG/SB/F/Ch), and induced neural tissue were generated by adding
NOG/SB to hESC cultures that were not treated with ActivinA (see,
e.g., Chambers S M, et al., Nat Biotechnol. 2009 Mar. 1;
27(3):275-80). By examining induction of the neural markers NESTIN,
SOX1, and PAX6, it was confirmed that these transcripts were highly
induced in dual NOG/SB neural cultures, but were low in ventral
foregut spheroid cultures. In contrast, FOXA2, which is expressed
in the foregut (see, e.g., Monaghan A P, et al., Development. 1993
November; 119(3):567-78; Ang S L, et al., Cell. 1994 Aug. 26;
78(4):561-74) and in some neural tissues (see, e.g., Spence J R, et
al., Nature. 2011 Feb. 3; 470(7332):105-9; Kroon E, et al., Nat
Biotechnol. 2008 Feb. 20; 26(4):443-52; Si-Tayeb K, et al.,
Hepatology. 2009 Oct. 1; 51(1):297-305; D'Amour K A, et al., Nat
Biotechnol [Internet]. 2005 Oct. 28; 23(12):1534-41; Stott S R W,
et al., Journal of Neuroscience. 2013 May 1; 33(18):8022-34;
D'Amour K A, et al., Nat Biotechnol. 2006 November;
24(11):1392-401; DeLaForest A, et al., Development. 2011 October;
138(19):4143-53), had high expression in ventral foregut spheroids,
but was significantly reduced in dual NOG/SB neural conditions
(FIG. 5). Taken together, these results strongly suggest spheroids
are indeed foregut, and not of neural origin.
Example II
[0146] This example shows induction of anterior foregut endoderm
into a lung lineage through modulation of FGF and HH signaling.
[0147] Many signaling pathways are important for lung induction and
development (see, e.g., Wong A P, et al., Nat Biotechnol. 2012 Aug.
26; Huang S X L, et al., Nature; 2013 Dec. 1; :1-11; Firth A L, et
al., Proceedings of the National Academy of Sciences. 2014 Apr. 29;
111(17):E1723-30; Mou H, et al., Cell Stem Cell. 2012 Apr. 6;
10(4):385-97; Ghaedi M, et al., J. Clin. Invest. 2013 Nov. 1;
123(11):4950-62; Longmire T A, et al., Cell Stem Cell. 2012 Apr. 6;
10(4):398-411; Rankin S A, Zorn A M. Gene Regulatory Networks
Governing Lung Specification. J Cell Biochem. 2014 Mar. 19;
Morrisey E E, et al., Developmental Cell. Elsevier Inc; 2010 Jan.
19; 18(1):8-23; Min H, et al., Genes & Development. 1998 Oct.
15; 12(20):3156-61; Weaver M, et al., Development. 2000 June;
127(12):2695-704). High levels of Fgf signaling have been shown to
induce Shh and Nkx2.1 expression in the foregut endoderm in mice
(see, e.g., Spence J R, et al., Nature. 2011 Feb. 3;
470(7332):105-9; D'Amour K A, et al., Nat Biotechnol. 2005 Oct. 28;
23(12):1534-41; Lancaster M A, et al., Nature. 2013 Sep. 19;
501(7467):373-9; Takebe T, et al., Nature. 2013 Jul. 25;
499(7459):481-4; Nakano T, et al., Cell Stem Cell. 2012 Jun. 14;
10(6):771-85; Meyer J S, et al., Stem Cells. 2011 Aug.;
29(8):1206-18; Hebrok M, et al., Genes & Development. 1998;
Serls A E.; Development. 2004 Dec. 2; 132(1):35-47); furthermore,
Gli2/3 null mouse embryos fail to form lungs (see, e.g., Spence J
R, et al., Nature. 2011 Feb. 3; 470(7332):105-9; Wells J M, et al.,
Development. 2014 February; 141(4):752-60; Motoyama J, et al., Nat
Genet. 1998 September; 20(1):54-7) and Hh signaling is important
for lung mesenchyme proliferation in vivo (see, e.g., Bellusci S,
et al., Development. 1997 January; 124(1):53-63). These data
confirm that Fgf and Hh signaling are critical for lung
specification and ligands from both signaling pathways have been
applied to hPSC derived lung lineages in 2D cultures (see, e.g.,
Spence J R, et al., Nature. 2011 Feb. 3; 470(7332):105-9; Wong A P,
et al., Nat Biotechnol. 2012 Aug. 26; Huang S X L, et al., Nat
Biotechnol; 2013 Dec. 1; :1-11). It has been reported that
approximately 85-95% of cells are endoderm, but a portion of the
remaining cells are mesodermal and this small mesodermal population
is maintained in the spheroids and organoids (see, e.g., Spence J
R, et al., Nature. 2011 Feb. 3; 470(7332):105-9; McCracken K W, et
al., Nature; 2014 Oct. 29; :1-19; Green M D, et al., Nat
Biotechnol.; 2011 Feb. 27; :1-7) (FIG. 4). Therefore, based on
mouse and hPSC studies, it was hypothesized that FGF and/or HH
signaling would induce an NKX2.1+ lung lineage in anterior foregut
endoderm. To test this hypothesis experiments initially focused on
adherent endoderm monolayer cultures to optimize induction
conditions. Cultures were treated for 4 days with ActivinA followed
by an additional 4 days with NOG/SB (referred to as Foregut).
Controls consisted of ActivinA treatment only followed by no
additional growth factors (Endoderm controls), or ActivinA followed
by NOG/SB, followed by no additional factors (Foregut controls).
All experimental groups were compared to both endoderm and foregut
controls (FIG. 6). The ability of FGF2 to induce SHH, NKX2.1 and
PAX8 was first tested by exposing foregut cultures to low and high
concentrations of FGF2 (50, 500 ng/mL) (FIG. 6A). A robust
concentration dependent increase in SHH and PAX8 mRNA expression
compared to foregut or endoderm controls was observed, and a modest
increase of NKX2.1 expression at the highest dose of FGF2 (500
ng/mL) (FIG. 6A). It was also observed that dual NOG/SB inhibition
in endoderm cultures induced robust NKX2.1 and PAX8 expression
without adding FGF2 (FIG. 1B, 6A). Thus, it was desired to
determine if NKX2.1 expression in foregut cultures was due to
endogenous FGF and/or HH signaling. To test this, the FGF or HH
pathway was inhibited with small molecules SU5402 (SU, 10 .mu.m)
and Sant-2 (10 .mu.m) respectively (FIG. 6B-C). Treating foregut
cultures with the FGF inhibitor SU caused a significant, robust
reduction in PAX8 and a modest reduction in SHH, while NKX2.1
expression was unchanged compared to foregut control (FIG. 6B).
Conversely, inhibition of HH signaling caused a significant
reduction in NKX2.1 expression, but not PAX8 compared to untreated
foregut. When FGF2 was added to the cultures, a modest increase in
NKX2.1 expression was observed, and when FGF was added along with
Sant-2, NKX2.1 expression was significantly reduced (FIG. 6C).
Together these results suggest a hierarchy where FGF is upstream of
SHH and PAX8, and where SHH is upstream of NKX2.1. To test if HH
signaling was able to induce NKX2.1 in foregut cultures, the
Smoothened agonist, SAG (1 .mu.M), was added to foregut cultures.
The addition of SAG induced a 6.5 fold increase of NKX2.1
expression above foregut controls (FIG. 6D). However, SAG alone did
not reduce PAX8 expression.
[0148] Based on these results, it was further hypothesized that
enhancing HH signaling would result in increased NKX2.1 expression
downstream of FGF, and that simultaneous inhibition of FGF
signaling would reduce PAX8 expression; therefore, endogenous FGF
signaling was inhibited with SU while activating HH with SAG (FIG.
6D). This combination caused an additional increase in NKX2.1
expression (21 fold vs. 6.5 fold with SAG only, when compared to
foregut) and a concomitant decrease in PAX8 mRNA (FIG. 6D).
Importantly, immunofluorescence correlated with QRT-PCR data
showing an increased number of NKX2.1+ cells with the addition of
SAG only. SAG+SU treated cultures showed a further increase in the
number of NKX2.1 expressing cells, with .about.77% of all cells
expressing NKX2.1 compared to .about.20% in foregut controls, and
nearly undetectable levels of PAX8 expressing cells (FIG. 7). SAG
and SAG+SU treated cells also co-expressed FOXA2 and SOX2
confirming their endodermal origin (FIG. 2).
Example III
[0149] This example shows that HH-induced foregut spheroids give
rise to human lung organoids (HLOs).
[0150] Based on the observations that stimulating HH and inhibiting
FGF signaling strongly enhances NKX2.1 expression while reducing
PAX8 expression (FIG. 5), multiple conditions of HH activation and
FGF inhibition to induce NKX2.1.sup.HI/PAX8.sup.LO foregut
spheroids (NOG/SB/F/Ch) were tested (FIG. 8). Consistent with the
important roles of FGF signaling in lung growth and branching
morphogenesis (see, e.g., Rankin S A, et al., J Cell Biochem. 2014
Mar. 19; Hebrok M, et al., Genes & Development. 1998; Morrisey
E E, et al., Developmental Cell.; 2010 Jan. 19; 18(1):8-23; Min H,
et al., Genes & Development. 1998 Oct. 15; 12(20):3156-61;
Weaver M, et al., Development. 2000 June; 127(12):2695-704; Abler L
L, et al., Dev. Dyn. 2009 August; 238(8):1999-2013), it was found
that conditions where FGF inhibition was used led to a reduction of
epithelial tissue relative to mesenchymal tissue, which could be
due to a loss of epithelium or an overgrowth of mesenchyme; this
suggests that endogenous FGF signaling is necessary to maintain the
epithelial tissue in 3D cultures (FIG. 9). Therefore, several
conditions were also tested that stimulated HH signaling using SAG
only, without FGF inhibition. It was found that the most efficient
method to enhance NKX2.1 expression was by adding SAG during the
foregut spheroid phase (FIG. 10A). Comparing foregut spheroids
(NOG/SB/F/Ch) with those treated with SAG (NOG/SB/F/Ch/SAG), a
substantial decrease in SOX2 expression compared to NOG/SB/F/Ch
spheroids was observed and a significant increase in NKX2.1 mRNA.
Additionally, nuclear NKX2.1 protein expression was found in ECAD+
epithelium which co-expressed endoderm epithelial markers FOXA2 and
SOX2 (FIG. 10B,C, FIG. 11). Interestingly, during lung
specification in mice, the gut tube initially expresses Sox2
throughout the endoderm, but Sox2 is down-regulated in the lung
field during lung specification and Nkx2.1 induction (see, e.g.,
Hebrok M, et al., Genes & Development. 1998; Serls A E.;
Development. 2004 Dec. 2; 132(1):35-47; Domyan E T, et al.,
Development. 2011 Feb. 8; 138(5):971-81). Thus, concomitant
down-regulation of SOX2 and increased NKX2.1 observed in SAG
treated foregut spheroids is consistent with early transcriptional
changes that occur during lung specification in mice.
[0151] It was also observed a slight, but non-significant increase
in PAX8 transcript level in NOG/SB/F/Ch/SAG treated foregut
spheroids (FIG. 10B). Importantly, PAX8 protein expression was
undetectable in NOG/SB/F/Ch/SAG treated foregut spheroids and
expression remained low/undetectable throughout time in culture
(FIG. 12). Similar to NOG/SB/F/Ch treated spheroids, the
NOG/SB/F/Ch/SAG treated spheroids had a minor population of cells
within the spheroids of mesodermal in origin, expressing Vimentin
(VIM) (FIG. 13).
[0152] NOG/SB/F/Ch/SAG treated foregut spheroids were embedded in
Matrigel to provide a 3D growth environment. Spheroids maintained
in basal media supplemented with 1% FBS lost ECAD+ epithelial
structures and were mainly comprised of mesenchyme within 20 days
of 3D culture (FIG. 9D,E). FGF10 is essential for branching
morphogenesis and maintenance of lung progenitor cells during
development as well as tissue homeostasis in the adult lung (see,
e.g., Motoyama J, et al., Nat Genet. 1998 September; 20(1):54-7; Li
Y, et al., Developmental Biology. 2004 Jun. 1; 270(1):214-31;
Bellusci S, et al., Development. 1997 January; 124(1):53-63; Min H,
et al., Genes & Development. 1998 Oct. 15; 12(20):3156-61;
Weaver M, et al., Development. 2000 June; 127(12):2695-704; Agha El
E, et al., Development. 2013 Dec. 18; Volckaert T, et al.,
Development 2013 Sep.; 140(18):3731-42). It was observed that the
addition of FGF10 (500 ng/mL) allowed spheroids to expand and be
passaged for over 100 days. FGF10 promoted the maintenance of ECAD+
epithelial structures with less mesenchymal contributions compared
to both basal and FGF inhibitor conditions (FIG. 10D).
NOG/SB/F/Ch/SAG cultured for 15 days in FGF10 possessed abundant
ECAD+ epithelium that expressed the proximal lung marker SOX2 and
distal lung marker SOX9. SOX2+ domains and SOX9+ domains were
distributed throughout the entire HLO as determined by whole mount
immunofluorescence and confocal Z-sections (FIG. 14). FGF10 treated
foregut spheroids maintained NKX2.1 expression over time; however,
consistent with mouse development, distal progenitor markers, NMYC
and ID2 mRNA expression decreased over time while distal Alveolar
Type I and II cell markers, HOPX and SFTPC increased over time
(see, e.g., Li Y, et al., Developmental Biology. 2004 Jun. 1;
270(1):214-31; Kimura S, et al., Genes Dev. Jan. 1; 10(1):60-9;
Yuan B, et al., Dev. Dyn. 2000 February; 217(2):180-90; Narumi S,
et al., Eur. J. Endocrinol. 2012 November; 167(5):625-32; Vilain C,
et al., J. Clin. Endocrinol. Metab. 2001 January; 86(1):234-8;
Mansouri A, et al., Nat Genet. 1998 May; 19(1):87-90; Kusakabe T,
et al., Mol. Endocrinol. 2006 August; 20(8):1796-809; Cane A, et
al., Hum. Mol. Genet. 2009 Jun. 15; 18(12):2266-76; Okubo T.;
Development. 2005 Feb. 9; 132(6):1363-74; Rawlins E L, et al.,
Development. 2009 November; 136(22):3741-5 (FIG. 10E). These data
suggest that HLOs pass through a stage resembling early fetal lung
development in mice.
Example IV
[0153] This example demonstrates that HLOs possess proximal
airway-like structures.
[0154] HLOs cultured longer than 2 months had striking epithelial
structures resembling proximal airways, expressing proximal cell
type-specific markers, including basal cells (P63), ciliated cells
(FOXJ1, ACTTUB) and club cells (SCGB1A1) (FIG. 15). Proximal-like
airway tissues were often surrounded by a smooth muscle actin
positive (SMA+) mesenchyme compartment. Although P63 mRNA
expression is maintained throughout culture (FIG. 15A), it is only
in prolonged cultures (>2 months) where the P63+ cells are
spatially arranged along the basal side of the epithelial tube-like
structures, adjacent to SMA+ mesenchyme, similar to human bronchi
and bronchioles (FIG. 15B) (see, e.g., Spence J R, et al., Nature.
2011 Feb. 3; 470(7332):105-9; D'Amour K A, et al., Nat Biotechnol.
2005 Oct. 28; 23(12):1534-41; Zhang M, Wang H, Teng H, Shi J, Zhang
Y. Expression of SHH signaling pathway components in the developing
human lung. Histochem. Cell Biol. 2010 October; 134(4):327-35;
Evans M J, et al., Exp. Lung Res. 2001 July; 27(5):401-15; Rock J
R, et al., Proceedings of the National Academy of Sciences. 2009
Aug. 4; 106(31):12771-5; Nakajima M, et al., Pathol. Int. 1998
December; 48(12):944-53; Boers J E, et al., American Journal of
Respiratory and Critical Care Medicine. 1998 June; 157(6 Pt
1):2000-6). By 65 days in vitro (D65) proximal-like epithelial
structures form a cyst-like structure that expresses P63, as
determined by whole mount immunofluorescence staining and confocal
z-stacks. Moreover, SMA expression is strongest at the periphery of
the HLO (FIG. 16). P63+ proximal airway-like cells also co-express
SOX2 and NKX2.1 as determined on serial sections (FIG. 17). Located
on the luminal surface of HLO proximal airway-like structures are
cells expressing the multi-ciliated cell transcription factor FOXJ1
(FIG. 15B). Very few cells expressed the club cell marker SCGB1A1,
and this protein was observed in a pixilated expression pattern
(FIG. 15D). Multi-ciliated and club cell specific mRNAs, FOXJJ and
SCGB1A1 respectively, were significantly increased in prolonged HLO
culture (FIG. 15A). Although the goblet cell marker MUC5AC mRNA
expression was detected, protein expression was not detected by
immunofluorescence (FIG. 15A).
[0155] Although the multi-ciliated cell transcription factor FOXJ1
was abundant in proximal airway-like structures, it was observed
that ACTTUB was localized to the apical side of these cells, but
did not appear to be localized to cilia on the apical cell surface
(FIG. 15C), suggesting that this may represent a cell that has not
fully differentiated. It has been demonstrated that robust
differentiation of multi-ciliated cells from hPSCs require modified
culture conditions to promote differentiation of functional cell
types (see, e.g., Firth A L, et al., Proceedings of the National
Academy of Sciences. 2014 Apr. 29; 111(17); Green M D, et al., Nat
Biotechnol; 2011 Feb. 27; :1-7; Loh K M, et al., Cell Stem Cell.
2014 Feb. 6; 14(2):237-52). Thus, it is possible that the HLO
environment, such as Matrigel or media rich in FGF10, does not
promote terminal differentiation of all cell types. In order to
alter the HLO environment, seeded NOG/SB/F/Ch/SAG foregut spheroids
were seeded onto an acellular human lung matrix (see, e.g., Green M
D, et al., Nat Biotechnol. Nature Publishing Group; 2011 Feb. 27;
:1-7; Booth A J, et al., American Journal of Respiratory and
Critical Care Medicine. 2012 Nov. 1; 186(9):866-76). Spheroids
seeded on slices of acellular lung matrix predominantly gave rise
to proximal airway-like structures in which stereotypical tufts of
ACTTUB positive ciliated structures on the apical surface of cells
were observed facing into a lumen. In serial sections, these
airways had abundant FOXJ1+ cells (FIG. 15E). Thus, HLOs have the
capacity to generate more mature ciliated cells given the correct
stimulus or environment.
[0156] As noted, proximal airways are often closely associated with
the SMA+ mesenchyme (FIG. 15B) whereas in the adult murine lung,
proximal airways are also associated with Pdgfr.alpha.+ and Vim+
mesenchymal cells (see, e.g., Chen L, et al., American Journal of
Respiratory Cell and Molecular Biology. 2012 October; 47(4):517-27;
Hinz B, et al., The American Journal of Pathology. 2007 June;
170(6):1807-16; Boucherat O, et al., American Journal of
Respiratory and Critical Care Medicine. 2007 May 15;
175(10):1066-77). Thus, the mesenchymal population within the HLOs
was investigated in more detail. Immunofluorescence revealed that
D65 HLOs have both PDGFR.alpha.+ NIM+ double positive and
PDGFR.alpha.-/VIM+ cell populations, which indicative of
myofibroblasts and fibroblasts respectively (FIG. 18A). Adult
murine myofibroblasts also co-express Sma and Pdgfr.alpha. whereas
differentiated smooth muscle is Sma+/Pdgfra- (see, e.g., Chen L, et
al., American Journal of Respiratory Cell and Molecular Biology.
2012 October; 47(4):517-27; Hinz B, et al., The American Journal of
Pathology. 2007 June; 170(6):1807-16; Boucherat O, et al., American
Journal of Respiratory and Critical Care Medicine. 2007 May 15;
175(10):1066-77; Leslie K O, et al., Differentiation. 1990 August;
44(2):143-9; Low R B, et al., Int. J. Biochem. Cell Biol. 1998
August; 30(8):869-83), and PDGFR.alpha.+/SMA+ and
PDGFR.alpha.-/SMA+ populations of cells were observed indicating
that HLOs possess myofibroblasts and smooth muscle cells (FIG.
18B). The HLOs did not stain positive for SafraninO indicating
there is no cartilage tissue, whereas iPSC derived teratomas had
abundant cartilage (FIG. 18C). Taken together, the HLO mesenchymal
population is diverse with myofibroblasts, fibroblasts, and smooth
muscle cells.
Example V
[0157] This example demonstrates that HLOs possess immature
alveolar airway-like structures.
[0158] The distal lung epithelium in mouse and human make up the
gas-exchanging alveoli, consisting of type I and type II alveolar
epithelial cells (AECI, AECII). During development, the distal lung
epithelium expresses progenitor markers including SOX9, ID2, and
NMYC (see, e.g., Spence J R, et al., Nature. 2011 Feb. 3;
470(7332):105-9; Green M D, et al., Nat Biotechnol.; 2011 Feb. 27;
:1-7; Xue X, et al., Gastroenterology. 2013 Jul. 13; Chen Y-J, et
al., Cell Rep.; 2014 Mar. 4; :1-13; Okubo T; Development. 2005 Feb.
9; 132(6):1363-74; Rawlins E L, et al., Development. 2009 November;
136(22):3741-5; Rockich B E, et al., Proceedings of the National
Academy of Sciences. 2013 Nov. 4; Chang D R, et al., Proceedings of
the National Academy of Sciences. 2013 Sep. 20). All distal markers
are present in the HLOs; however, ID2 and NMYC are expressed at
high levels in early cultures, but are down regulated in prolonged
culture (FIG. 10F) while SOX9 expression remains consistent across
time in culture (FIG. 19A).
[0159] Recently, there have been major advances in mice toward
defining a bipotent alveolar progenitor population during the late
fetal/early neonatal period (see, e.g., Desai T J, et al., Nature.
2014 Feb. 5; Treutlein B, et al., Nature. 2014 May 15;
509(7500):371-5; Chambers S M, et al., Nat Biotechnol. 2009 Mar. 1;
27(3):275-80), and this work has highlighted the fact that many
markers previously considered terminal differentiation markers are
co-expressed in the bipotent progenitors. Specifically, the AECII
marker SftpC and AECI marker Hopx can be co-expressed in a bipotent
progenitor before becoming committed to one lineage or the other.
Moreover, it has been shown that Sox9 marks an early progenitor
population in the developing mouse lung and Sox9 also marks the
bipotent progenitor in late fetal life (see, e.g., Treutlein B, et
al., Nature. 2014 May 15; 509(7500):371-5; Monaghan A P, et al.,
Development. 1993 November; 119(3):567-78; Ang S L, et al., Cell.
1994 Aug. 26; 78(4):561-74; Rockich B E; et la., Proceedings of the
National Academy of Sciences. 2013 Nov. 4). In HLOs grown in
prolonged culture (>2 months), it was observed that AECII
(SFTPC, SFTPB) and AECI (PDPN, HOPX) cell-type markers were present
(FIG. 19A-B). However, it was also observed that SFTPC levels were
very low (FIG. 10F), and that SFTPB+ cells were rare (FIG. 19B).
This suggested that the distal airway cells present in HLOs might
be a progenitor-like population. To test this possibility, SFTPC
(AECII) or HOPX (AECI) was co-stained with SOX9 and abundant
SFTPC/SOX9 and HOPX/SOX9 double positive cells were found (FIG.
19B). Co-staining in serial sections suggests that SFTPC/SOX9
double positive cells are also NKX2.1+ (FIG. 20). In contrast these
co-expressing cells were not found in the adult human lung (FIG.
19C). Although rare, the few SFTPB+ observed in HLOs resemble AECII
cells seen in the adult human lung, and PDPN+ cells resembled the
elongated AECI cells in the human lung (FIG. 19B-C). In order to
improve confidence that cells expressing AECII markers are AECII
cells, transmission electron microscopy (TEM) was used to determine
if HLOs possessed cells containing lamellar bodies, which are
necessary for surfactant protein trafficking and secretion (see,
e.g., Weaver T E, et al., Seminars in Cell & Developmental
Biology. 2002 August; 13(4):263-70; Schmitz G, et al., J. Lipid
Res. 1991 October; 32(10):1539-70; Stahlman M T, et al., Lab.
Invest. 2000 March; 80(3):395-403). Using TEM, lamellar bodies were
observed both in cells within HLOs, and in open spaces between
cells, indicating that lamellar bodies are being secreted (FIG.
19D). Taken together, these data suggest that HLOs predominantly
possess an undifferentiated alveolar progenitor cells with rare
differentiated AECI and AECII cells interspersed throughout the
distal-like tissue.
Example VI
[0160] This example provides a quantitative assessment of HLO
composition.
[0161] It has been shown that HLOs have both proximal-like and
distal-like epithelium in addition to surrounding mesenchymal
tissue. In order to better gauge the composition of HLOs, a
detailed quantitative analysis of cell types and structures was
performed. 48 individual HLOs were sectioned and examined for P63+
proximal airway-like structures (FIG. 15B-D), and distal-airway
like structures (FIG. 20). It was found that 39/48 (81%) of the
HLOs have proximal airway epithelial structures while 48/48 (100%)
of HLOs have distal airway-like structures (FIG. 21A). The average
cross-sectional area comprised of P63+ proximal airway-like and
P63- distal airway-like tissue were calculated and it was found
that proximal structures comprised 14.5% (+/-0.6%) of the entire
area of the HLO, whereas 85.5% (+/-0.6%) were distal in nature
(including epithelium and mesenchyme) (FIG. 21B). To determine the
percentage of certain cell types within an HLO, 15 individual HLOs
(n=15) were sectioned and stained, cells positive for specific
markers counted, and the total number of Dapi+ nuclei within a
section determined (FIG. 217C-G). On average, 57% of all cells in
the HLOs were NKX2.1+ (FIG. 21C), 39% of all cells were P63+, 3%
were FOXJ1+, 5% were SFTPC+4% of all cells were HOPX+ (FIG.
21D-G).
Examplve VII
[0162] This example demonstrates that HLOs are globally similar to
human fetal lung.
[0163] Accumulating evidence suggests that HLOs are immature. For
example, distal progenitor markers are initially robustly expressed
whereas SFTPC expression is very low across time in HLOs (FIG.
10E), FOXJ1+ cells do not appear to form mature multi-ciliated
structures until placed onto a decelluarized lung matrix (FIG. 15B,
E) and rare SCGB1A1+ cells do not resemble mature club cells (FIG.
15D). Moreover, the majority of the distal-like epithelium
expresses bipotent progenitor markers (FIG. 19). In order to
directly address the maturity of HLOs, RNA-sequencing (RNAseq) was
conducted on HLOs (n=6; 3 D65 HLOs, 3 D110 HLOs), on
undifferentiated hESCs, and on definitive endoderm. Publicly
available RNAseq datasets were utilized for human fetal lung
representing a range of gestational stages, and for adult human
lung (FIG. 22). In order to determine global similarity among these
tissues relative to HLOs, principal component (PC) analysis was
conducted (FIG. 23A,B) (see e.g., Ringner M.; Nat Biotechnol. 2008
March; 26(3):303-4), hierarchical clustering (FIG. 238C) (see,
e.g., Eisen, et al., PNAS Dec. 8, 1998 vol. 95 no. 25 14863-14868),
and Spearmans rank-order correlation matrix analysis (FIG. 23D) of
the complete tabulated FPKM matrix generated from RNA sequences
datasets and representing the total gene expression complement in
each sample (see, e.g., Daxin Jiang, et al., IEEE Trans. Knowl.
Data Eng. 2004 November; 16(11):1370-86). Consistent across all
three types of informatics analysis, transcriptional activity in
the HLOs shares the greatest degree of similarity to human fetal
lung. These data strongly suggest that global transcription of HLOs
is highly similar to human fetal lung, and support the idea that
HLOs are in a less differentiated, fetal state when grown in the
conditions described here.
Example VIII
[0164] This example provides the materials and methods relating to
Examples I-VII.
Maintenance of hESCs
[0165] Human ES cell lines H1 (NIH registry #0043) and H9 (NIH
registry #0062) were obtained from WiCell Research Institute. Human
ES line UM77-2 (NIH registry #0278) was obtained from the
University of Michigan. iPSC lines 3-5 and 20-1 were generated at
Cincinnati Children's Hospital and have been previously described
(see, e.g., Spence J R, et al., Nature. 2011 Feb. 3;
470(7332):105-9). Stem cells were maintained on Matrigel (BD
Biosciences) in mTesR1 medium (STEM CELL Technologies). HESCs were
passaged as previously described (see, e.g., Spence J R, et al.,
Nature. 2011 Feb. 3; 470(7332):105-9).
Differentiation of PSCs into Definitive Endoderm
[0166] Differentiation into definitive endoderm was carried out as
previously described (see, e.g., Spence J R, et al., Nature. 2011
Feb. 3; 470(7332):105-9; D'Amour K A; et al., Nat Biotechnol
[Internet]. 2005 Oct. 28; 23(12):1534-41). Briefly, a 4-day Activin
A (R&D systems) differentiation protocol was used. Cells were
treated with Activin A (100 ng ml.sup.-1) for three consecutive
days in RPMI 1640 media (Life Technologies) with increasing
concentrations of 0%, 0.2% and 2% HyClone defined fetal bovine
serum (dFBS, Thermo Scientific).
Differentiation of Definitive Endoderm into Anterior Foregut
[0167] After differentiation into definitive endoderm, foregut
endoderm was differentiated, essentially as described (see, e.g.,
Green M D, et al., Nat Biotechnol. Nature Publishing Group; 2011
Feb. 27; :1-7). Briefly, cells were incubated in foregut media:
Advanced DMEM/F12 plus N-2 and B27 supplement, 10 mM Hepes, lx
L-Glutamine (200 mM), lx Penicillin-streptomycin (5,000 U/mL, all
from Life Technologies) with 200 ng/mL Noggin (NOG, R&D
Systems) and 10 .mu.M SB431542 (SB, Stemgent) for 4 days. For long
term maintenance, cultures were maintain in "basal" foregut media
without NOG and SB, or in the presence of growth factors including
50, 500 ng/mL FGF2 (R&D systems), 10 .mu.M Sant-2 (Stemgent),
10 .mu.M SU5402 (SU, Stemgent), 100 ng/mL SHH (R&D systems),
and 1 .mu.M SAG (Enzo Life Sciences) for 8 days.
Directed Differentiation into Anterior Foregut Spheroids and Lung
Organoids
[0168] After differentiation into definitive endoderm, cells were
incubated in foregut media with NOG, SB, 500 ng/mL FGF4 (R&D
Systems), and 2 .mu.M CHIR99021 (Chiron, Stemgent) for 4-6 days.
After 4 days with treatment of growth factors, three-dimensional
floating spheroids were present in the culture. Three-dimensional
spheroids were transferred into Matrigel to support 3D growth as
previously described (see, e.g., McCracken K W, et al., Nature
Protocols; 2011 Nov. 10; 6(12):1920-8). Briefly, spheroids were
embedded in a droplet of Matrigel (BD Bioscience #356237) in one
well of a 24 well plate, and incubated at room temperature for 10
minutes. After the Matrigel solidified, foregut media with 1% Fetal
bovine serum (FBS, CAT #: 16000-044, Life Technologies) or other
growth factors and small molecules were overlaid and replaced every
4 days. Organoids were transferred into new Matrigel droplets every
10 to 15 days.
Immunohistochemistry
[0169] Immunostaining was carried out as previously described
(64,84). Antibody information and dilutions can be found in FIG.
24. All images were taken on a Nikon A1 confocal microscope or an
Olympus IX71 epifluorescent microscope.
RNA Extraction and qRT-PCR
[0170] RNA was extracted from monolayers, spheroids, and organoids
using a MagMAX-96 Total RNA Isolation Kit (Life Technologies) and
MAG Max Express (Applied Biosystems). RNA quantity and quality were
determined spectrophotometrically, using a Nano Drop 2000
(Thermoscientific). Reverse transcription was conducted using the
SuperScript VILO kit (Invitrogen), according to manufacturer's
protocol. Finally, qRT-PCR was carried out using Quantitect Sybr
Green MasterMix (Qiagen) on a Step One Plus Real-Time PCR system
(Life Technologies). A list of primer sequences is provided in FIG.
25.
Seeding Lung Spheroids on Decellularized Human Lung Matrices
[0171] Human lungs deemed to be unsuitable for lung transplantation
were obtained from beating-heart (or warm autopsy) donors through
Gift of Life Michigan and lungs were decellularized as previously
described (see, e.g., Booth A J, et al., American Journal of
Respiratory and Critical Care Medicine. 2012 Nov. 1;
186(9):866-76). Slices were prepared using a sterile tissue punch
(Fisher) and sterilized with 0.18% peracetic acid and 4.8% EtOH.
Matrix slices were placed in a 96 well plate and approximately 50
NOG+SB+F+Ch+SAG spheres were pipetted directly onto the matrices.
Samples were centrifuged for 2 min at 2000 rpm and then incubated
at 37 C for 30 min without media. Foregut media supplemented with
1% FBS and 500 ng/mL FGF10 was then added to the matrices. Media
was changed daily.
Transmission Electron Microscopy
[0172] D50 HLOs were processed as previously described (see, e.g.,
Rockich B E, et al., Proceedings of the National Academy of
Sciences. 2013 Nov. 4; Prasov L, et al., Neuroreport. 2012 Jul. 11;
23(10):631-4). 70 nm sections were sections were imaged using a
Philips CM-100 electron microscope.
Area and Cell Quantification
[0173] HLOs with P63+ cells were counted as having proximal
airway-like epithelium and HLOs with SFTPC+ cells were counted as
having distal airway-like epithelium. The area of proximal
epithelium was determined by P63+ ECAD+ staining. Area was measured
using ImageJ software. Cell quantification of NKX2.1, P63, and DAPI
was counted by Metamorph cell counting software. FOXJ1, SFTPC, and
HOPX were counted in ImageJ using the cell counter plugin.
Statistical Analysis and Experimental Replicates
[0174] All immunofluorescence and qRT-PCR experiments were carried
out at least two times with three (n=3) independent biological
samples per experiment. The only exceptions to this were
experiments that included human adult lung samples in the analysis.
For these experiments, n=1 biological human lung sample was used in
statistical replicates (triplicates) whereas all other samples used
biological replicates (n=3). For quantification in FIG. 21, a total
of 48 different HLOs (n=48) were counted for HLO composition. For
the proximal epithelial area, 29 different HLOs were counted
(n=29). For cell quantification, 15 different HLOs were counted
(n=15). Statistical differences between groups were assessed with
Prism software, using multiple t tests. All error bars represent
SEM. Results were considered statistically significant at
P<0.05.
RNA Sequencing and Analysis
[0175] Sequencing of HLOs (n=3 D65, n=3 D110) was performed by the
University of Michigan DNA Sequencing Core, using the Illumina
Hi-Seq platform. Sequencing of H9 Stem Cells (SC) and Definitive
Endoderm (DE) was performed by the University of California, San
Francisco DNA Sequencing Core using the Illumina Hi-Seq platform.
All sequences were deposited in the EMBL-EBI ArrayExpress database
using Annotare 2.0 and are catalogued under the accession number
E-MTAB-3339 for the HLOs and E-MTAB-3158 for SC and DE. The
University of Michigan Bioinformatics Core obtained the reads files
and concatenated those into a single .fastq file for each sample.
The Bioinformatics Core also downloaded reads files from EBI-AE
database (Adult lung Samples) and NCBI-GEO (SRA) database (Fetal
lung samples) (FIG. 22). The quality of the raw reads data for each
sample was evaluated using FastQC (version 0.10.1) to identify
features of the data that may indicate quality problems (e.g. low
quality scores, over-represented sequences, inappropriate GC
content, etc.). Initial QC report indicated over-representation of
Illumina adapter sequences in samples from EBI-AE data set and
NCBI-GEO data set. Adapter sequences were trimmed from the reads
using Cutadapt (version 0.9.5) see, e.g., Chen C, et al., Source
Code Biol Med. 2014; 9:8). Briefly, reads were aligned to the
reference transcriptome (UCSC hg19) using TopHat (version 2.0.9)
and Bowtie (version 2.1.0.0) see, e.g., Langmead B, et al., Genome
Biol. 2009; 10(3):R25). Cufflinks/CuffNorm (version 2.2.1) were
used for expression quantitation and differential expression
analysis (see, e.g., Trapnell C, et al., Nature Protocols. 2012
March; 7(3):562-78), using UCSC hg19.fa as the reference genome
sequence and UCSC hg19.gtf as the reference transcriptome
annotation. For this analysis, parameter settings:
"-multi-read-correct" were used to adjust expression calculations
for reads that map in more than one locus, as well as
"-compatible-hits-norm" and "-upper-quartile-norm" for
normalization of expression values. Normalized FPKM tables were
generated using the CuffNorm function found in Cufflinks.
Transcriptional quantitation analysis in Cufflinks was conducted
using the 64-bit Debian Linux stable version 7.8 ("Wheezy")
platform. The complete FPKM matrix, containing frequency counts for
all 24,010 genes contained in the reference genome for all 23
RNAseq samples, was evaluated using unscaled principle component
analysis (PCA) to visualize and quantify multi-dimensional
variation between samples (see, e.g., Ringner M.; Nat Biotechnol.
2008 March; 26(3):303-4). Of the 24,010 genes annotated in the
reference genome, 2,815 (11.7%) were not detected in the RNAseq
analysis of any of the 23 samples. Principle components were
calculated using the function `prcomp` found in the R (version
3.1.2) statistical programming language (http://www.R-project.org/)
and plotted using the R package `ggplot2` (see, e.g., Wickham H.;
ggplot2: Elegant Graphics for Data Analysis--Hadley Wickham--Google
Books. 2009). Hierarchical cluster analysis based on the Canberra
distance (see, e.g., Eisen, et al., PNAS Dec. 8, 1998 vol. 95 no.
25 14863-14868) between FPKM vectors was used to classify discrete
RNAseq samples according to the degree of total transcriptional
dissimilarity indicated by the normalized FPKM values. Bootstrap
analysis was used to assess the uncertainty in the assigned
hierarchical clustering relationships. 10,000 bootstraping
iterations were generated by repeatedly randomly sampling the FPKM
dataset. The bootstrap probability (BP) of a cluster is defined as
the frequency of a given relationship among the bootstrap
replicates. Multiscale bootstrap resampling was used to calculate
an approximately unbiased (AU) p-value for a given relationship,
with AU >95 indicating a high degree of statistical
significance. Analyses were conducted using R package `pvclust`
(see, e.g., Suzuki R, et al., Bioinformatics. 2006 Jun. 15;
22(12):1540-2). Spearman correlation was applied as an additional
assessment of the cumulative degree of correlation among RNAseq
datasets. In addition, Spearman rank correlation coefficients (p)
in a pairwise manner among all 23 RNAseq samples using the complete
normalized FPKM data. The Spearman coefficients were plotted as a
heatmap using the function `heatmap.2` in the R package `gplots`
(http://CRAN.R-project.org/package=gplots). Complete data analysis
scripts are available at
https://github.com/hilldr/HLO_eLife2015.
[0176] Having now fully described the invention, it will be
understood by those of skill in the art that the same can be
performed within a wide and equivalent range of conditions,
formulations, and other parameters without affecting the scope of
the invention or any embodiment thereof. All patents, patent
applications and publications cited herein are fully incorporated
by reference herein in their entirety.
INCORPORATION BY REFERENCE
[0177] The entire disclosure of each of the patent documents and
scientific articles referred to herein is incorporated by reference
for all purposes.
EQUIVALENTS
[0178] The invention may be embodied in other specific forms
without departing from the spirit or essential characteristics
thereof. The foregoing embodiments are therefore to be considered
in all respects illustrative rather than limiting the invention
described herein. Scope of the invention is thus indicated by the
appended claims rather than by the foregoing description, and all
changes that come within the meaning and range of equivalency of
the claims are intended to be embraced therein.
Sequence CWU 1
1
38120DNAArtificial Sequencesynthetic 1gggctctctg agaggcaggt
20220DNAArtificial Sequencesynthetic 2ggtgacggtg gggtttagca
20319DNAArtificial Sequencesynthetic 3ttgacgccga gagctacac
19419DNAArtificial Sequencesynthetic 4gaccggtgca atcttcaaa
19521DNAArtificial Sequencesynthetic 5cgactggagc agctactatg c
21620DNAArtificial Sequencesynthetic 6tacgtgttca tgccgttcat
20720DNAArtificial Sequencesynthetic 7caacttctgc tacttccgcc
20819DNAArtificial Sequencesynthetic 8cgaggcactt tgatgaagc
19918DNAArtificial Sequencesynthetic 9cctctgtacc ccttcccg
181020DNAArtificial Sequencesynthetic 10ggggctccag agtagaggtt
201119DNAArtificial Sequencesynthetic 11gcctttccga ggaggagac
191220DNAArtificial Sequencesynthetic 12tctgtgacgg atctgcactc
201320DNAArtificial Sequencesynthetic 13gacagcaaag cactgtgtgg
201422DNAArtificial Sequencesynthetic 14tcagcactta aaagattccg tg
221523DNAArtificial Sequencesynthetic 15gcaccaacga caggaaggat gag
231620DNAArtificial Sequencesynthetic 16cacgttccag agccggacat
201718DNAArtificial Sequencesynthetic 17ctcatgttca tgccgctc
181819DNAArtificial Sequencesynthetic 18gacaccatga ggaacagcg
191920DNAArtificial Sequencesynthetic 19cacagtgacc acgtcgattt
202020DNAArtificial Sequencesynthetic 20cacaaggccc tcagtacctc
202120DNAArtificial Sequencesynthetic 21ccacagtaca cgaacctggg
202221DNAArtificial Sequencesynthetic 22ccgttctgaa tctgctggtc c
212320DNAArtificial Sequencesynthetic 23tgcctcacaa ctccatcaga
202418DNAArtificial Sequencesynthetic 24caggtctacg atgcgctg
182520DNAArtificial Sequencesynthetic 25acatcctttg tttttgccca
202620DNAArtificial Sequencesynthetic 26agtgtcatct tctggctggc
202718DNAArtificial Sequencesynthetic 27cgtccgcttg ttctcctc
182820DNAArtificial Sequencesynthetic 28cctttcccat ggatgaagtc
202920DNAArtificial Sequencesynthetic 29atgaaactcg ctgtcaccct
203020DNAArtificial Sequencesynthetic 30gtttcgatga cacgctgaaa
203120DNAArtificial Sequencesynthetic 31agcaaagagg tcctgatgga
203220DNAArtificial Sequencesynthetic 32cgataagaag gcgtttcagg
203320DNAArtificial Sequencesynthetic 33gcttagcctc gtcgatgaac
203420DNAArtificial Sequencesynthetic 34aaccccaaga tgcacaactc
203519DNAArtificial Sequencesynthetic 35gtacccgcac ttgcacaac
193619DNAArtificial Sequencesynthetic 36gtggtccttc ttgtgctgc
193720DNAArtificial Sequencesynthetic 37cttcagagag aggaagccga
203820DNAArtificial Sequencesynthetic 38attccacttt gcgttcaagg
20
* * * * *
References